- Published on
Medicine – Causes of Diabetes Insipidus
Diabetes insipidus – DI is a disorder of water balance characterised by the production of large volumes of abnormally dilute urine. The resulting excessive urinary water loss produces polyuria and polydipsia, and if the patient cannot replace the lost water, hypernatraemia and dehydration may develop.
The two major forms in the original notes are:
Central DI – reduced secretion of antidiuretic hormone.
Nephrogenic DI – reduced renal response to antidiuretic hormone.
The older term cranial DI is still understood, but central diabetes insipidus is now more commonly used.
1. Normal ADH Physiology
Antidiuretic hormone – ADH, also called:
Arginine vasopressin – AVP,
is synthesised mainly in the:
Supraoptic and paraventricular nuclei of the hypothalamus.
It is transported along axons to the:
Posterior pituitary,
where it is stored and released into the circulation.
2. Action of ADH
ADH acts mainly on:
V₂ receptors
on principal cells of the renal collecting ducts.
This activates signalling that inserts:
Aquaporin-2 water channels
into the luminal membrane.
Therefore:
ADH → V₂ receptor → aquaporin-2 insertion → ↑ water reabsorption → concentrated urine.
3. What Happens in Diabetes Insipidus?
If there is insufficient ADH:
Collecting ducts cannot conserve water effectively.
Alternatively, ADH may be present but the kidneys may fail to respond.
In either situation:
↓ Water reabsorption
↓
Large-volume dilute urine
↓
Polyuria
↓
Thirst and polydipsia
↓
If water intake is inadequate:
Hypernatraemia + increased plasma osmolality + dehydration.
4. Central Diabetes Insipidus
Central DI results from inadequate synthesis or secretion of:
ADH/AVP.
Therefore:
↓ ADH secretion → collecting duct cannot maximally concentrate urine → excessive free-water loss.
The major causes include:
Idiopathic/autoimmune disease.
Pituitary or hypothalamic surgery.
Trauma.
Tumours.
Infiltrative diseases.
Genetic disorders.
5. Idiopathic Central DI
The original notes correctly include:
Idiopathic central DI.
This means no obvious structural cause is identified during the initial evaluation.
Some cases previously classified as idiopathic are now recognised to have:
Autoimmune
or other identifiable mechanisms.
Therefore appropriate follow-up may still be required.
6. Pituitary Surgery
The original notes correctly identify:
Pituitary surgery
as an important cause.
Surgery around the:
Hypothalamus.
Pituitary stalk.
Posterior pituitary.
can disrupt the hypothalamic neurons or axons responsible for ADH transport and release.
Therefore:
PITUITARY/HYPOTHALAMIC SURGERY → ↓ ADH → CENTRAL DI.
7. Postoperative DI
Central DI may appear after surgery involving the pituitary region.
Depending on the degree of injury, it may be:
Transient
or
Permanent.
Patients require careful monitoring of:
Urine output.
Serum sodium.
Fluid balance.
8. Infiltrative Hypothalamic Disease
Infiltrative diseases can damage the:
Hypothalamus
or
Pituitary stalk.
The original notes correctly include:
Sarcoidosis
and
Histiocytosis X.
9. Sarcoidosis
Sarcoidosis can involve the hypothalamic–pituitary region as part of:
Neurosarcoidosis.
Granulomatous infiltration can interfere with ADH production or release.
Therefore:
SARCOIDOSIS → HYPOTHALAMIC/PITUITARY INFILTRATION → CENTRAL DI.
Interestingly, sarcoidosis can also contribute to nephrogenic DI indirectly through hypercalcaemia, which impairs the kidney’s concentrating ability.
10. Histiocytosis X
The older term:
Histiocytosis X
is now generally replaced by:
Langerhans cell histiocytosis – LCH.
LCH can infiltrate the:
Hypothalamic–pituitary axis.
Central DI is an important endocrine manifestation.
Therefore:
LCH + POLYURIA/POLYDIPSIA → CONSIDER CENTRAL DI.
11. Craniopharyngioma
The original notes correctly include:
Craniopharyngioma.
These tumours occur close to the:
Pituitary stalk and hypothalamus.
They may damage the ADH-producing or transporting system.
Therefore central DI may develop either from the:
Tumour itself
or following:
Surgery for the tumour.
12. Other Tumours
Other masses affecting the hypothalamic–pituitary region may also cause central DI.
Examples include selected:
Germ-cell tumours.
Metastases.
Other suprasellar lesions.
The important principle is:
Damage to the hypothalamus or pituitary stalk can impair ADH secretion.
13. Trauma
The original notes correctly include:
Trauma.
Severe head injury may damage the:
Hypothalamus.
Pituitary stalk.
Posterior pituitary pathway.
This can produce:
Transient or permanent central DI.
14. Familial Central DI
Rare genetic disorders can cause central DI.
These may involve abnormalities in:
AVP synthesis or processing.
Some familial forms are inherited in an:
Autosomal dominant pattern.
15. DIDMOAD Syndrome
The original notes correctly identify:
DIDMOAD syndrome.
DIDMOAD stands for:
Diabetes Insipidus.
Diabetes Mellitus.
Optic Atrophy.
Deafness.
This disorder is also known as:
Wolfram syndrome.
16. Wolfram Syndrome
Wolfram syndrome is a rare genetic neurodegenerative disorder, classically associated with:
Juvenile-onset diabetes mellitus.
Optic atrophy.
Central diabetes insipidus.
Sensorineural deafness.
Therefore:
DIDMOAD = DI + DM + OPTIC ATROPHY + DEAFNESS.
This is a useful examination mnemonic.
17. Nephrogenic Diabetes Insipidus
In nephrogenic DI, ADH is produced and released, but the kidneys are:
Resistant to its action.
Therefore:
ADH present
↓
Kidney fails to respond adequately
↓
Aquaporin-mediated water reabsorption impaired
↓
Large-volume dilute urine.
18. Causes of Nephrogenic DI
Nephrogenic DI can be:
Inherited
or
Acquired.
Acquired causes are considerably more common and include:
Lithium.
Hypercalcaemia.
Hypokalaemia.
Kidney disease.
Post-obstructive states.
Other medications can also impair renal concentrating ability.
19. Inherited Nephrogenic DI
The original notes state:
Primary X-linked or dominant.
This requires some refinement.
The most common inherited form is:
X-linked nephrogenic DI
caused by abnormalities in the:
AVPR2 gene, which encodes the renal V₂ vasopressin receptor.
20. Aquaporin-2 Mutations
Other inherited forms are caused by mutations involving:
Aquaporin-2 – AQP2.
These can be:
Autosomal recessive
or, less commonly:
Autosomal dominant.
Therefore the inheritance pattern depends on the molecular defect.
21. Hypercalcaemia
The original notes correctly identify:
Hypercalcaemia
as a cause of nephrogenic DI.
Persistent high calcium interferes with the kidney’s ability to:
Concentrate urine.
It impairs responsiveness of the collecting duct to ADH and can affect the medullary concentration gradient.
Therefore:
HYPERCALCAEMIA → IMPAIRED URINARY CONCENTRATION → POLYURIA → NEPHROGENIC DI.
22. Hypokalaemia
The original notes also correctly include:
Hypokalaemia.
Persistent potassium deficiency reduces the kidney’s ability to concentrate urine and can impair:
Aquaporin-2 expression and collecting-duct responsiveness.
Therefore:
HYPOKALAEMIA → ADH RESISTANCE/IMPAIRED CONCENTRATION → NEPHROGENIC DI.
23. Chronic Kidney Disease and Tubulointerstitial Disease
Several forms of renal disease impair the kidney’s concentrating ability.
The original notes include:
Chronic pyelonephritis.
Adult polycystic kidney disease.
Post-urinary obstruction.
These can produce a nephrogenic DI-like concentrating defect.
24. Chronic Pyelonephritis
Chronic tubulointerstitial injury can damage the structures required to maintain:
The renal medullary concentration gradient.
As a result, the kidney becomes less capable of concentrating urine even when ADH is present.
Therefore:
CHRONIC TUBULOINTERSTITIAL DAMAGE → IMPAIRED CONCENTRATING ABILITY → POLYURIA.
25. ADPKD
The older term:
Adult polycystic kidney disease
is better expressed as:
Autosomal dominant polycystic kidney disease – ADPKD.
Structural disruption of the renal medulla can impair urinary concentrating ability.
Patients may therefore develop:
Polyuria and nocturia, particularly as renal disease progresses.
26. Post-Urinary Obstruction
The original notes correctly include:
Post-urinary obstruction.
After relief of significant urinary obstruction, patients may develop:
Post-obstructive diuresis.
Tubular dysfunction and reduced responsiveness to ADH may contribute to very large urine volumes.
This can cause substantial losses of:
Water and electrolytes.
27. Lithium
The original notes correctly identify:
Lithium
as a major drug cause of nephrogenic DI.
This is one of the most important acquired causes.
Lithium enters collecting-duct principal cells and interferes with:
ADH signalling
and
Aquaporin-2 expression/function.
Therefore:
LITHIUM → COLLECTING-DUCT ADH RESISTANCE → NEPHROGENIC DI.
28. Clinical Importance of Lithium
Patients taking chronic lithium therapy may develop:
Polyuria.
Polydipsia.
Impaired urinary concentrating ability.
The concentrating defect can sometimes persist even after lithium is discontinued, particularly after prolonged exposure.
29. Demeclocycline
The original notes correctly include:
Demeclocycline.
Demeclocycline reduces renal responsiveness to:
ADH.
It can therefore intentionally produce a form of:
Nephrogenic DI.
Historically, this effect has been used in selected patients with:
SIADH.
Its use is now more limited because of concerns such as:
Nephrotoxicity and the availability of other approaches.
30. Glibenclamide – Important Correction
The original notes include:
Glibenclamide
as a cause of nephrogenic DI.
This is not a standard modern cause of nephrogenic diabetes insipidus and should not be memorised as one of the major drug associations.
The high-yield drug causes are much more importantly:
Lithium.
Demeclocycline.
Other recognised drug-related causes include selected nephrotoxic agents that impair tubular function.
31. Sarcoidosis and Nephrogenic DI
The original notes also list:
Sarcoidosis
under nephrogenic DI.
This can occur indirectly because sarcoidosis may produce:
Hypercalcaemia.
Hypercalcaemia then impairs the renal response to ADH.
Therefore sarcoidosis can potentially contribute to DI by two different mechanisms:
Hypothalamic/pituitary involvement → central DI.
or
Hypercalcaemia → nephrogenic DI.
32. Clinical Features of DI
The characteristic symptoms are:
Polyuria.
Polydipsia.
Nocturia.
The urine is:
Dilute.
Patients often develop a strong preference for:
Cold water.
33. Hypernatraemia
If thirst is intact and water is freely available, patients can often compensate for urinary losses by drinking large quantities of water.
Therefore serum sodium may remain:
Normal.
However, if the patient cannot obtain enough water:
Free-water loss exceeds intake
↓
Serum Na⁺ rises
↓
Plasma osmolality rises
↓
Hypernatraemic dehydration develops.
34. When DI Becomes Particularly Dangerous
DI becomes especially dangerous in patients who:
Cannot communicate thirst.
Cannot access water.
Are unconscious.
Are very young.
Have neurological impairment.
These patients can develop severe:
Hypernatraemia and dehydration.
35. Diagnosis
The first step is to establish that the patient truly has:
Hypotonic polyuria.
This requires distinguishing DI from other causes of frequent or excessive urination.
Important measurements include:
24-hour urine volume.
Urine osmolality.
Serum sodium.
Plasma osmolality.
Glucose.
Calcium.
Potassium.
Renal function.
36. Exclude Osmotic Diuresis
A major differential diagnosis is:
Diabetes mellitus.
In uncontrolled diabetes mellitus:
Glucose spills into urine
↓
Water follows glucose
↓
Osmotic diuresis
↓
Polyuria.
The urine in diabetes mellitus may therefore have a relatively high osmolality because of:
Glucose.
In DI, the urine is characteristically:
Inappropriately dilute.
37. Primary Polydipsia
Another important differential is:
Primary polydipsia.
Here the primary problem is:
Excessive water intake
rather than failure of ADH production or action.
Excess water intake suppresses ADH and produces:
Dilute urine.
Therefore distinguishing primary polydipsia from partial DI can sometimes be challenging.
38. Water-Deprivation Testing
Traditionally, selected patients were investigated using a supervised:
Water-deprivation test.
The principle is to determine whether the kidney can appropriately concentrate urine when water is withheld.
In healthy physiology:
Water deprivation → ↑ ADH → concentrated urine.
In DI:
Urine remains inappropriately dilute.
Because dehydration can become dangerous, this test requires:
Careful specialist supervision.
39. Desmopressin Response
Desmopressin – DDAVP is an ADH analogue.
After desmopressin:
Central DI → urine concentration rises substantially, because the missing hormone has been replaced.
In:
Nephrogenic DI → little or no appropriate response, because the kidney remains resistant to ADH.
Partial forms may show intermediate responses.
40. Copeptin – Modern Diagnostic Addition
Modern specialist evaluation may use:
Copeptin.
Copeptin is released with endogenous vasopressin and is easier to measure reliably than ADH itself.
Stimulated copeptin-based testing can help distinguish:
Central DI.
Nephrogenic DI.
Primary polydipsia.
This is increasingly important in specialist diagnostic pathways.
41. Treatment of Central DI
The major treatment for established central DI is:
Desmopressin – DDAVP.
It acts mainly at renal:
V₂ receptors
and increases collecting-duct water reabsorption.
Therefore:
DESMOPRESSIN → ↑ WATER REABSORPTION → ↓ URINE VOLUME.
42. Desmopressin Safety
Excessive desmopressin combined with excessive water intake can cause:
Water retention
and
Hyponatraemia.
Therefore therapy requires appropriate monitoring and patient education.
The underlying cause of central DI should also be treated when possible.
43. Treatment of Nephrogenic DI
Treatment begins by correcting the cause.
Examples include:
Correct hypercalcaemia.
Correct hypokalaemia.
Review or stop lithium when clinically appropriate.
Treat underlying renal disease.
Adequate access to water is essential.
44. Thiazides in Nephrogenic DI
Paradoxically:
Thiazide diuretics
can reduce urine volume in nephrogenic DI.
They cause mild volume contraction, increasing proximal sodium and water reabsorption.
Therefore less fluid reaches the distal nephron.
The result is:
Reduced urine volume.
45. Amiloride and Lithium-Induced DI
In lithium-induced nephrogenic DI:
Amiloride
can be particularly useful because it blocks:
ENaC
and reduces lithium entry into collecting-duct principal cells.
Therefore:
LITHIUM-INDUCED DI → CONSIDER AMILORIDE.
46. Central DI – Note Form
CENTRAL DI = TOO LITTLE ADH.
Idiopathic/autoimmune.
Pituitary/hypothalamic surgery.
Trauma.
Infiltrative disease:
Sarcoidosis.
Langerhans cell histiocytosis.
Tumours:
Craniopharyngioma.
Other hypothalamic/pituitary stalk lesions.
Genetic:
Familial central DI.
Wolfram syndrome – DIDMOAD.
47. Nephrogenic DI – Note Form
NEPHROGENIC DI = ADH PRESENT BUT KIDNEY DOES NOT RESPOND PROPERLY.
Inherited:
X-linked AVPR2 mutations.
AQP2 mutations – usually AR, sometimes AD.
Electrolytes:
Hypercalcaemia.
Hypokalaemia.
Renal disease:
Chronic tubulointerstitial disease/chronic pyelonephritis.
ADPKD with concentrating defect.
Post-obstructive state.
Drugs:
Lithium – particularly important.
Demeclocycline.
Other causes of significant tubular injury.
Sarcoidosis:
Can cause nephrogenic concentrating impairment indirectly through:
Hypercalcaemia.
48. Central Versus Nephrogenic DI – Copyable Comparison
CENTRAL DI
Problem:
↓ ADH secretion.
Site of defect:
Hypothalamus/posterior pituitary pathway.
Desmopressin:
Urine concentrating response present, especially in complete central DI.
Typical causes:
Surgery, trauma, craniopharyngioma, sarcoidosis, LCH, idiopathic/autoimmune and genetic disease.
NEPHROGENIC DI
Problem:
↓ renal response to ADH.
Site of defect:
Kidney/collecting duct.
Desmopressin:
Little or no response in complete nephrogenic DI.
Typical causes:
Lithium, hypercalcaemia, hypokalaemia, renal tubular disease and inherited AVPR2/AQP2 abnormalities.
49. Important Clarifications to the Original Notes
The term:
“Cranial DI”
is valid historically, but:
Central diabetes insipidus
is the more commonly used modern term.
ADH is:
Synthesised in the hypothalamus
and then:
Transported to and released from the posterior pituitary.
Therefore central DI may result from damage anywhere along this pathway.
The older term:
Histiocytosis X
should generally be replaced by:
Langerhans cell histiocytosis.
The original inherited nephrogenic DI description of:
“X-linked or dominant”
needs refinement:
AVPR2 mutations → usually X-linked.
AQP2 mutations → usually autosomal recessive, occasionally autosomal dominant.
The original inclusion of:
Glibenclamide
as a major drug cause is outdated and should not be prioritised.
The major examination drug association is:
LITHIUM → NEPHROGENIC DI.
Key Clinical Pattern
For rapid recall:
DI → POLYURIA + POLYDIPSIA + LARGE VOLUMES OF DILUTE URINE.
CENTRAL DI = NOT ENOUGH ADH.
Think:
PITUITARY SURGERY.
HEAD TRAUMA.
CRANIOPHARYNGIOMA.
SARCOIDOSIS.
LANGERHANS CELL HISTIOCYTOSIS.
WOLFRAM/DIDMOAD.
NEPHROGENIC DI = KIDNEYS DO NOT RESPOND TO ADH.
Think:
LITHIUM.
HYPERCALCAEMIA.
HYPOKALAEMIA.
RENAL TUBULAR/CHRONIC KIDNEY DISEASE.
AVPR2/AQP2 MUTATIONS.
And remember the classic treatment distinction:
CENTRAL DI → DESMOPRESSIN.
NEPHROGENIC DI → CORRECT CAUSE ± THIAZIDE; AMILORIDE PARTICULARLY USEFUL FOR LITHIUM-INDUCED DI.
- Published on
Medicine – Causes of Hypokalaemia
Hypokalaemia is a reduction in serum potassium concentration, usually defined as:
K⁺ <3.5 mmol/L.
Potassium is the major intracellular cation and is essential for normal neuromuscular function, skeletal-muscle contraction and cardiac electrical activity. Significant hypokalaemia can therefore cause weakness, paralysis and potentially dangerous cardiac arrhythmias.
The causes can be understood through three major mechanisms:
Decreased potassium intake.
Increased potassium loss from the body.
Redistribution of potassium from extracellular fluid into cells.
1. Decreased Potassium Intake
Reduced dietary potassium intake alone is an:
Uncommon cause of hypokalaemia.
This is because potassium is widely distributed in food and the kidneys can reduce urinary potassium excretion when intake falls.
Therefore substantial hypokalaemia from reduced intake usually requires:
Severe or prolonged nutritional deficiency
or another contributing mechanism.
2. Starvation
The original notes correctly identify:
Starvation
as a situation in which oral potassium intake can become sufficiently low to contribute to hypokalaemia.
Patients with prolonged:
Malnutrition.
Anorexia.
Starvation.
may develop depletion of total-body potassium.
Other electrolyte deficiencies, particularly:
Magnesium and phosphate deficiency,
may coexist.
3. Inadequate Parenteral Potassium
Hospitalised patients who cannot eat and receive prolonged intravenous fluids without sufficient potassium replacement may develop:
Hypokalaemia.
This is especially likely when there are simultaneous ongoing potassium losses from:
Urine.
Vomiting.
Diarrhoea.
Nasogastric drainage.
Therefore the original note:
“Parenteral”
refers more accurately to inadequate potassium provision during parenteral therapy.
4. Increased Potassium Loss
Increased potassium loss is one of the most important mechanisms of hypokalaemia.
Losses can occur through:
Gastrointestinal tract
or
Kidneys.
A useful clinical question is therefore:
Is the potassium being lost through the gut or through the urine?
5. Gastrointestinal Potassium Loss
Important gastrointestinal causes include:
Vomiting.
Severe diarrhoea.
Laxative/purgative abuse.
Villous adenoma.
Other causes include prolonged gastrointestinal drainage and some fistulas.
6. Vomiting
The original notes correctly include:
Vomiting.
However, an important physiological point is that hypokalaemia from vomiting is not simply due to large amounts of potassium being lost directly in vomit.
Gastric fluid contains mainly:
Hydrogen ions and chloride.
The major potassium loss occurs secondarily through the:
Kidneys.
7. Why Vomiting Causes Hypokalaemia
Persistent vomiting causes:
Loss of HCl
↓
Metabolic alkalosis
- ●
Volume and chloride depletion
↓
Activation of:
Renin–angiotensin–aldosterone system – RAAS
↓
↑ Aldosterone
↓
↑ Distal sodium reabsorption
↓
↑ Renal K⁺ secretion
↓
Hypokalaemia.
Therefore:
VOMITING → METABOLIC ALKALOSIS + SECONDARY HYPERALDOSTERONISM → RENAL K⁺ LOSS.
8. Severe Diarrhoea
The original notes correctly identify:
Severe diarrhoea
as an important cause.
Intestinal fluid contains significant potassium.
Therefore prolonged high-volume diarrhoea can cause direct:
Gastrointestinal K⁺ loss.
9. Diarrhoea and Acid–Base Balance
Diarrhoea also causes loss of:
Bicarbonate.
Therefore the classic biochemical pattern is:
Hypokalaemia
- ●
Normal-anion-gap metabolic acidosis.
This contrasts with vomiting, which typically produces:
Hypokalaemia + metabolic alkalosis.
10. Purgative or Laxative Abuse
Chronic excessive use of laxatives can produce:
Persistent diarrhoea
and therefore:
Potassium depletion.
Severe laxative abuse may result in substantial electrolyte disturbances and volume depletion.
Therefore:
LAXATIVE ABUSE → DIARRHOEA → GI K⁺ LOSS → HYPOKALAEMIA.
11. Villous Adenoma
A large secretory:
Villous adenoma of the colon or rectum
can produce substantial amounts of watery, electrolyte-rich diarrhoea.
This can cause:
Hypokalaemia.
Volume depletion.
Renal impairment.
The severe secretory syndrome associated with a large villous adenoma is sometimes called:
McKittrick–Wheelock syndrome.
12. Renal Potassium Loss
The kidneys are another major route of excessive potassium loss.
Important renal causes include:
Thiazide diuretics.
Loop diuretics.
Renal tubular disorders.
Mineralocorticoid excess.
Hypomagnesaemia.
13. Thiazide Diuretics
The original notes correctly include:
Thiazides.
Examples include:
Bendroflumethiazide.
Hydrochlorothiazide.
Indapamide.
Thiazides inhibit sodium chloride reabsorption in the:
Distal convoluted tubule.
This increases sodium delivery to the collecting duct.
14. Why Thiazides Cause Hypokalaemia
More sodium reaches the distal nephron.
↓
More sodium enters principal cells through:
ENaC.
↓
The lumen becomes relatively negative.
↓
Potassium secretion increases.
↓
Hypokalaemia.
Volume contraction also activates:
RAAS and aldosterone,
further promoting potassium loss.
15. Loop Diuretics
Loop diuretics such as:
Furosemide
inhibit the:
Na⁺-K⁺-2Cl⁻ cotransporter – NKCC2
in the thick ascending limb of the loop of Henle.
This increases distal sodium delivery and promotes:
Renal potassium excretion.
Therefore:
LOOP DIURETICS → HYPOKALAEMIA.
16. Diuretics and Metabolic Alkalosis
Both loop and thiazide diuretics commonly produce:
Hypokalaemia
and
Metabolic alkalosis.
This occurs through increased distal sodium delivery, volume contraction and increased aldosterone activity.
Therefore:
DIURETIC + LOW K⁺ + METABOLIC ALKALOSIS
is a classic clinical pattern.
17. Renal Tubular Damage
The original notes include:
Renal tubular damage.
Tubular disorders can impair normal electrolyte handling and cause inappropriate urinary potassium loss.
Examples include certain:
Tubulointerstitial diseases.
Drug-induced tubular injury.
Inherited tubular disorders.
The exact acid–base pattern depends on which part of the nephron is affected.
18. Renal Tubular Acidosis
Certain forms of:
Renal tubular acidosis – RTA
are associated with hypokalaemia.
These include:
Type 1 – distal RTA.
Type 2 – proximal RTA.
Both can produce:
Hypokalaemic normal-anion-gap metabolic acidosis.
In contrast:
Type 4 RTA causes hyperkalaemia.
19. Hypomagnesaemia
An important additional cause of persistent renal potassium loss is:
Hypomagnesaemia.
Low magnesium increases renal potassium secretion.
Therefore:
↓ Mg²⁺ → ↑ renal K⁺ wasting → hypokalaemia.
This is particularly important when potassium remains low despite replacement.
20. Refractory Hypokalaemia
A high-yield clinical rule is:
HYPOKALAEMIA THAT DOES NOT CORRECT → CHECK MAGNESIUM.
Potassium replacement may be ineffective until associated magnesium deficiency is also corrected.
21. Endocrine Causes
The original notes identify three important mineralocorticoid-related causes:
Primary hyperaldosteronism.
Cushing syndrome.
Excess liquorice consumption.
These conditions increase renal potassium excretion.
22. Primary Hyperaldosteronism – Conn Syndrome
In primary hyperaldosteronism:
Aldosterone production is excessive and relatively autonomous.
Aldosterone increases sodium reabsorption through ENaC in the collecting duct while increasing:
Potassium secretion
and
Hydrogen ion secretion.
Therefore the classic pattern is:
Hypertension + hypokalaemia + metabolic alkalosis.
23. Renin and Aldosterone in Primary Hyperaldosteronism
Because sodium retention expands extracellular volume, renin secretion becomes suppressed.
Therefore:
Aldosterone ↑
while:
Renin ↓.
This produces an increased:
Aldosterone-to-renin ratio.
However, not every patient with primary aldosteronism is hypokalaemic; many are:
Normokalaemic.
24. Cushing Syndrome
In severe cortisol excess, cortisol can exert:
Mineralocorticoid effects.
This increases sodium retention and promotes renal:
Potassium and hydrogen ion loss.
Therefore severe Cushing syndrome may produce:
Hypertension.
Hypokalaemia.
Metabolic alkalosis.
25. Liquorice
The original notes correctly identify:
Excess liquorice
as a cause of hypokalaemia.
However, liquorice does not simply contain a conventional mineralocorticoid.
Its active component:
Glycyrrhetinic acid
inhibits:
11β-hydroxysteroid dehydrogenase type 2 – 11β-HSD2.
26. Mechanism of Liquorice-Induced Hypokalaemia
Normally 11β-HSD2 converts:
Cortisol → cortisone
within mineralocorticoid-sensitive tissues.
When the enzyme is inhibited:
Cortisol activates mineralocorticoid receptors.
↓
↑ Na⁺ retention
↓
↑ K⁺ and H⁺ excretion
↓
Hypertension + hypokalaemia + metabolic alkalosis.
This resembles mineralocorticoid excess.
27. Redistribution Into Cells
Hypokalaemia does not always mean potassium has been lost from the body.
Sometimes total-body potassium is relatively preserved, but potassium moves:
From extracellular fluid → into cells.
This lowers the measured serum potassium.
Important causes include:
Metabolic alkalosis.
Insulin.
β₂-adrenergic agonists.
Correction of severe megaloblastic anaemia.
Hypothermia.
28. Metabolic Alkalosis
The original notes correctly include:
Metabolic alkalosis.
During alkalosis, potassium tends to shift:
Into cells.
Hydrogen ions move in the opposite direction to help maintain electroneutrality.
Additionally, many causes of metabolic alkalosis, such as vomiting and diuretic therapy, simultaneously cause:
Renal potassium loss.
Therefore hypokalaemia and metabolic alkalosis commonly reinforce one another.
29. Insulin
The original notes correctly identify:
Insulin.
Insulin stimulates:
Na⁺/K⁺-ATPase.
This drives potassium:
From extracellular fluid → into cells.
Therefore insulin lowers serum potassium.
30. Clinical Importance of Insulin
This physiological effect is deliberately used when treating:
Hyperkalaemia.
Intravenous insulin with glucose shifts potassium into cells and temporarily lowers serum K⁺.
Conversely, excessive insulin activity can contribute to:
Hypokalaemia.
31. β-Adrenergic Agonists
The original notes correctly include:
β-adrenergic agonists, particularly β₂ agonists such as:
Salbutamol.
β₂-receptor stimulation increases Na⁺/K⁺-ATPase activity.
Therefore:
Salbutamol → K⁺ moves into cells → serum K⁺ falls.
This is also why nebulised salbutamol can be used as an adjunct in the treatment of:
Hyperkalaemia.
32. Vitamin B12 or Folate Treatment
The original notes include:
Vitamin B12 or folic acid when correcting megaloblastic anaemia.
This is a recognised but less common mechanism.
When severe megaloblastic anaemia is treated, effective erythropoiesis can increase rapidly.
New cells take up:
Potassium.
Therefore serum potassium can transiently fall.
33. Mechanism During Haematological Recovery
Vitamin B12/folate treatment
↓
Rapid increase in erythropoiesis
↓
Increased cellular uptake of K⁺
↓
Transient hypokalaemia.
This is most relevant in patients with severe deficiency undergoing brisk marrow recovery.
34. Hypothermia
The original notes also include:
Hypothermia.
Hypothermia can cause potassium to move:
Into cells
and may increase renal potassium loss.
Therefore serum potassium may fall during significant hypothermia.
An important clinical consideration is that potassium may rise again during:
Rewarming.
35. Clinical Features of Hypokalaemia
Mild hypokalaemia may be:
Asymptomatic.
With increasing severity, patients may develop:
Fatigue.
Muscle weakness.
Muscle cramps.
Constipation or ileus.
Paraesthesiae.
Severe deficiency can cause:
Flaccid paralysis.
Respiratory muscle weakness.
Cardiac arrhythmias.
36. ECG Changes
Hypokalaemia can produce characteristic ECG abnormalities.
These may include:
Flattened or inverted T waves.
ST-segment depression.
Prominent U waves.
Apparent QT/QU prolongation.
Severe hypokalaemia increases susceptibility to:
Atrial and ventricular arrhythmias.
37. Hypokalaemia and Digoxin
Hypokalaemia increases myocardial sensitivity to:
Digoxin.
Therefore a patient receiving digoxin who develops significant hypokalaemia has an increased risk of:
Digoxin toxicity and arrhythmias.
This is particularly important when hypokalaemia is caused by:
Loop or thiazide diuretics.
38. Investigation
The first step is to confirm the potassium abnormality and look for the underlying mechanism.
Useful investigations include:
Serum electrolytes.
Magnesium.
Renal function.
Bicarbonate/acid–base status.
ECG when clinically significant.
If the cause remains uncertain, urinary potassium can help determine whether potassium loss is:
Renal or extrarenal.
39. Urinary Potassium
Conceptually:
Low urinary K⁺ during hypokalaemia
suggests that the kidneys are appropriately conserving potassium.
This points toward:
GI loss, poor intake or intracellular redistribution.
In contrast:
Inappropriately high urinary K⁺
suggests:
Renal potassium wasting.
This may occur with:
Diuretics.
Mineralocorticoid excess.
Renal tubular disorders.
Hypomagnesaemia.
40. Blood Pressure and Acid–Base Status
A particularly useful diagnostic approach is to combine:
Blood pressure
with
Acid–base status.
For example:
Hypokalaemia + metabolic alkalosis + hypertension
suggests:
Mineralocorticoid excess, such as primary aldosteronism.
Hypokalaemia + metabolic alkalosis + normal/low BP
suggests possibilities such as:
Vomiting.
Diuretics.
Bartter syndrome.
Gitelman syndrome.
Hypokalaemia + metabolic acidosis
suggests:
Diarrhoea
or
Type 1/type 2 RTA, among other causes.
41. Treatment Principles
Treatment depends on:
Severity of hypokalaemia.
Symptoms.
ECG abnormalities.
Underlying cause.
Renal function.
Presence of hypomagnesaemia.
The underlying potassium loss or redistribution should be corrected whenever possible.
42. Potassium Replacement
Mild-to-moderate hypokalaemia is often treated with:
Oral potassium replacement.
More severe or symptomatic hypokalaemia may require carefully controlled:
Intravenous potassium replacement
with appropriate monitoring.
Intravenous potassium must be administered cautiously because excessive or rapid administration can cause:
Dangerous hyperkalaemia and cardiac arrhythmias.
43. Correct Magnesium
If hypomagnesaemia is present:
Replace magnesium as well.
Otherwise continued renal potassium wasting can make hypokalaemia:
Difficult or impossible to correct adequately.
44. Causes of Hypokalaemia – Note Form
DECREASED INTAKE:
Starvation/severe malnutrition.
Inadequate potassium during prolonged parenteral therapy.
Usually insufficient alone unless prolonged or combined with other losses.
GI LOSS:
Vomiting.
Severe diarrhoea.
Purgative/laxative abuse.
Villous adenoma.
RENAL LOSS:
Thiazide diuretics.
Loop diuretics.
Renal tubular disease.
Type 1 and type 2 RTA.
Hypomagnesaemia.
ENDOCRINE/MINERALOCORTICOID:
Primary hyperaldosteronism – Conn syndrome.
Cushing syndrome.
Excess liquorice.
REDISTRIBUTION INTO CELLS:
Metabolic alkalosis.
Insulin.
β₂ agonists such as salbutamol.
B12/folate treatment during brisk recovery from severe megaloblastic anaemia.
Hypothermia.
45. Acid–Base Patterns – Note Form
Vomiting:
Hypokalaemia
- ●
Metabolic alkalosis.
Loop/thiazide diuretics:
Hypokalaemia
- ●
Metabolic alkalosis.
Primary hyperaldosteronism:
Hypertension
- ●
Hypokalaemia
- ●
Metabolic alkalosis.
Severe diarrhoea:
Hypokalaemia
- ●
Normal-anion-gap metabolic acidosis.
Type 1 or type 2 RTA:
Hypokalaemia
- ●
Normal-anion-gap metabolic acidosis.
46. Important Clarifications to the Original Notes
The original list is broadly correct.
Reduced oral intake alone is an uncommon cause unless severe or prolonged, such as starvation.
Vomiting causes hypokalaemia mainly through:
Volume/chloride depletion → RAAS activation → aldosterone-mediated renal K⁺ loss, rather than simply direct potassium loss from gastric fluid.
Excess liquorice does not literally act simply as an ingested mineralocorticoid. It inhibits:
11β-HSD2
allowing cortisol to activate mineralocorticoid receptors.
An important addition to the original list is:
Hypomagnesaemia, because it causes renal potassium wasting and is a major reason hypokalaemia may fail to respond to potassium replacement.
Key Clinical Pattern
For rapid recall:
HYPOKALAEMIA = LOW INTAKE, LOSS, OR SHIFT INTO CELLS.
Think:
VOMITING → LOW K⁺ + METABOLIC ALKALOSIS.
DIARRHOEA → LOW K⁺ + NORMAL-GAP METABOLIC ACIDOSIS.
LOOP/THIAZIDE → LOW K⁺ + METABOLIC ALKALOSIS.
CONN → HYPERTENSION + LOW K⁺ + METABOLIC ALKALOSIS.
INSULIN / SALBUTAMOL → K⁺ SHIFTS INTO CELLS.
LOW Mg²⁺ → RENAL K⁺ WASTING → REFRACTORY HYPOKALAEMIA.
For the ECG:
FLAT T WAVES + ST DEPRESSION + PROMINENT U WAVES → THINK HYPOKALAEMIA.
And the particularly useful clinical rule is:
HYPOKALAEMIA THAT WILL NOT CORRECT → CHECK AND REPLACE MAGNESIUM.
- Published on
Medicine – Hyperkalaemia
Hyperkalaemia is an abnormally high serum potassium concentration. It is clinically important because potassium strongly influences the resting membrane potential of cardiac and skeletal muscle cells, and severe hyperkalaemia can cause rapidly progressive conduction abnormalities, ventricular arrhythmias and cardiac arrest.
A commonly used definition is:
Serum K⁺ >5.0–5.5 mmol/L, depending on the laboratory.
The urgency of treatment depends not only on the potassium concentration but also on the ECG, symptoms, rate of rise, renal function and underlying cause.
1. Major Mechanisms of Hyperkalaemia
The causes can be divided into four useful groups:
Spurious or pseudohyperkalaemia.
Excess potassium administration.
Reduced renal potassium excretion.
Redistribution of potassium from cells into extracellular fluid.
This classification helps determine whether the patient has genuine excess total-body potassium or simply a shift of potassium from the intracellular to extracellular compartment.
2. Spurious Hyperkalaemia
Before treating an unexpected potassium result, consider:
Pseudohyperkalaemia.
This means the measured potassium is elevated in the blood sample even though the patient’s true circulating potassium is not significantly elevated.
The classic cause is:
Haemolysis of the blood sample.
3. Haemolysis
Red blood cells contain a high intracellular concentration of potassium.
If red cells rupture during or after venepuncture:
Intracellular K⁺ is released into the sample.
↓
Laboratory potassium rises.
↓
Falsely elevated potassium result.
Therefore:
UNEXPECTED HIGH K⁺ + HAEMOLYSED SAMPLE → CONSIDER PSEUDOHYPERKALAEMIA.
However, if the potassium is severely elevated or the ECG is abnormal, urgent management should not be delayed simply while waiting for a repeat result.
4. Other Causes of Pseudohyperkalaemia
Pseudohyperkalaemia can also occur with:
Difficult or traumatic venepuncture.
Prolonged tourniquet application.
Repeated fist clenching during blood collection.
Marked thrombocytosis.
Marked leukocytosis.
Therefore the blood result should always be interpreted in its clinical context.
5. Excessive Potassium Intake
The original notes place excessive intake under “spurious,” but this requires correction.
Excessive potassium intake causes genuine hyperkalaemia, not pseudohyperkalaemia.
This may occur from:
Excessive intravenous potassium administration.
Excessive oral potassium supplements.
Potassium-containing salt substitutes.
Dietary potassium alone rarely causes severe hyperkalaemia when renal function and aldosterone activity are normal because healthy kidneys can increase potassium excretion.
The risk becomes much greater in:
Kidney failure or impaired aldosterone activity.
6. Decreased Renal Potassium Excretion
The kidneys are the major route for potassium elimination.
Therefore:
Reduced renal K⁺ excretion
is one of the most important mechanisms of hyperkalaemia.
Major causes include:
Acute kidney injury.
Chronic kidney disease.
Hypoaldosteronism.
Addison disease.
Potassium-retaining medications.
7. Acute Kidney Injury
The older term:
Acute oliguric renal failure
is now generally replaced by:
Acute kidney injury – AKI.
Severe AKI, particularly when associated with:
Oliguria or anuria,
can markedly reduce urinary potassium excretion.
Therefore potassium accumulates in the extracellular fluid.
8. Why Hyperkalaemia Is Dangerous in AKI
AKI may simultaneously produce:
Reduced potassium excretion
and
Metabolic acidosis.
Acidosis may further increase extracellular potassium in some settings.
Therefore:
AKI + OLIGURIA + ACIDOSIS → HIGH RISK OF HYPERKALAEMIA.
Severe refractory hyperkalaemia is an important indication for:
Urgent dialysis.
9. Chronic Kidney Disease
The older term:
Chronic renal failure
is now generally replaced by:
Chronic kidney disease – CKD.
As functioning nephron mass falls, the kidneys become progressively less able to excrete potassium.
Adaptive mechanisms can maintain potassium balance for a considerable period, so severe hyperkalaemia is particularly likely in:
Advanced CKD
or when an additional precipitant is present.
10. Common Precipitants in CKD
A patient with CKD may develop hyperkalaemia after:
AKI.
Dehydration.
ACE inhibitor or ARB therapy.
Potassium-sparing diuretics.
NSAIDs.
Excess potassium supplementation.
Metabolic acidosis.
Therefore medication review is essential.
11. Aldosterone and Potassium
Aldosterone normally acts on the distal nephron to promote:
Sodium reabsorption
and
Potassium secretion.
Therefore:
↓ Aldosterone production or action → ↓ renal K⁺ excretion → hyperkalaemia.
12. Addison Disease
Addison disease, or primary adrenal insufficiency, causes deficiency of:
Aldosterone
and
Cortisol.
Aldosterone deficiency reduces renal potassium excretion.
Therefore:
ADDISON DISEASE → ↓ ALDOSTERONE → K⁺ RETENTION → HYPERKALAEMIA.
Hyponatraemia may occur simultaneously.
13. Hypoaldosteronism
Other forms of hypoaldosteronism can also cause hyperkalaemia.
An important example is:
Hyporeninaemic hypoaldosteronism, often associated with diabetic kidney disease and type 4 renal tubular acidosis.
The characteristic pattern may include:
Hyperkalaemia + mild normal-anion-gap metabolic acidosis.
14. Spironolactone
Spironolactone is a mineralocorticoid receptor antagonist.
It blocks the action of:
Aldosterone.
This decreases potassium secretion in the collecting duct.
Therefore:
Spironolactone → K⁺ retention → hyperkalaemia.
The risk is greater in CKD or when combined with other drugs that suppress the renin–angiotensin–aldosterone system.
15. Amiloride
Amiloride blocks epithelial sodium channels:
ENaC
in the collecting duct.
This decreases the electrochemical gradient that normally promotes potassium secretion.
Therefore:
Amiloride → ↓ renal K⁺ secretion → hyperkalaemia.
16. ACE Inhibitors
ACE inhibitors reduce:
Angiotensin II
and consequently reduce:
Aldosterone secretion.
Therefore:
ACE inhibitor → ↓ aldosterone → ↓ K⁺ excretion → hyperkalaemia.
Examples include:
Ramipril.
Lisinopril.
Enalapril.
The risk increases in patients with:
CKD, diabetes, AKI or concurrent potassium-retaining medications.
17. Angiotensin Receptor Blockers
An important addition is:
ARBs, such as losartan.
Like ACE inhibitors, they reduce aldosterone activity and can therefore cause:
Hyperkalaemia.
18. NSAIDs
NSAIDs inhibit renal prostaglandin synthesis.
This can reduce renal perfusion and suppress:
Renin release.
Reduced renin leads to reduced aldosterone activity.
Therefore:
NSAIDs → ↓ renin/aldosterone + possible AKI → hyperkalaemia.
The risk is especially important in patients with pre-existing:
CKD or volume depletion.
19. Other Drugs Causing Hyperkalaemia
Important additional medications include:
Trimethoprim, which has an amiloride-like effect on ENaC.
Heparin, which can reduce aldosterone synthesis.
Tacrolimus and ciclosporin.
ARBs.
Potassium supplements.
Therefore unexplained hyperkalaemia should always trigger a:
Medication review.
20. Redistribution of Potassium
Most body potassium is normally located:
Inside cells.
Certain conditions cause potassium to move from the intracellular compartment into extracellular fluid.
This produces:
Redistribution hyperkalaemia.
Important examples include:
Acidosis.
Rhabdomyolysis.
Tumour lysis syndrome.
Digoxin toxicity.
Insulin deficiency and hyperglycaemic hyperosmolality can also contribute.
21. Acidosis
The original notes correctly include:
Acidosis.
In some forms of metabolic acidosis, particularly mineral/inorganic acid acidosis, extracellular H⁺ promotes movement of potassium out of cells.
Therefore:
H⁺ moves into cells
while:
K⁺ moves out
to help maintain electroneutrality.
This contributes to:
Hyperkalaemia.
22. Important Acidosis Clarification
The relationship between acidosis and potassium is not identical in every type of acidosis.
Hyperkalaemia is particularly associated with:
Mineral acidosis
and with conditions involving:
Insulin deficiency, hyperosmolality or impaired renal function.
Organic acidoses do not necessarily cause the same degree of direct H⁺/K⁺ exchange.
23. Rhabdomyolysis
Skeletal muscle cells contain large amounts of intracellular potassium.
In rhabdomyolysis:
Muscle cells break down.
↓
Intracellular K⁺ is released.
↓
Hyperkalaemia develops.
Other substances released include:
Myoglobin.
Phosphate.
Creatine kinase.
Hyperkalaemia may become especially severe if rhabdomyolysis also causes:
AKI.
24. Tumour Lysis Syndrome
Tumour lysis syndrome occurs when large numbers of malignant cells rapidly break down.
Cellular contents enter the circulation, producing:
Hyperkalaemia.
Hyperphosphataemia.
Hyperuricaemia.
Secondary:
Hypocalcaemia.
Therefore:
TUMOUR LYSIS → ↑ K⁺ + ↑ PHOSPHATE + ↑ URIC ACID + ↓ Ca²⁺.
25. Digoxin Toxicity
The original notes correctly include:
Digoxin poisoning.
Digoxin inhibits:
Na⁺/K⁺-ATPase.
In acute severe toxicity, potassium movement into cells is reduced.
Therefore extracellular potassium rises:
Acute digoxin toxicity → hyperkalaemia.
The degree of hyperkalaemia can be an important marker of severe acute toxicity.
26. ECG Changes in Hyperkalaemia
Hyperkalaemia alters myocardial depolarisation and repolarisation.
The traditional sequence is:
Peaked T waves
↓
PR prolongation
↓
P-wave flattening
↓
P-wave disappearance
↓
QRS widening
↓
Sine-wave pattern
↓
Ventricular fibrillation or asystole.
However, the ECG does not always progress predictably, and dangerous hyperkalaemia can occasionally exist without classic ECG changes.
27. Peaked T Waves
An early classic ECG manifestation is:
Tall, narrow, peaked or “tented” T waves.
These reflect altered ventricular:
Repolarisation.
They may be particularly prominent in the:
Precordial leads.
28. P-Wave Changes
As hyperkalaemia becomes more severe:
P-wave amplitude decreases.
This reflects impaired atrial conduction.
Eventually:
P waves may disappear completely.
29. PR Prolongation
The:
PR interval increases
as atrioventricular conduction slows.
Therefore:
Hyperkalaemia → conduction slowing → PR prolongation.
30. QRS Widening
Further elevation of potassium causes slowing of ventricular depolarisation.
Therefore:
QRS complexes become progressively wider.
Marked QRS widening is a dangerous sign of severe cardiac toxicity.
31. Sine-Wave Pattern
In extreme hyperkalaemia:
Widened QRS complexes merge with T waves.
This produces a:
Sine-wave or sinusoidal appearance.
This represents:
Pre-terminal cardiac toxicity
and may rapidly progress to:
Ventricular fibrillation or asystole.
32. ECG Changes – Note Form
T waves:
Tall + peaked + tented.
↓
P waves:
Become smaller.
↓
PR interval:
Prolongs.
↓
P waves:
May disappear.
↓
QRS:
Widens.
↓
QRS + T merge:
Sine-wave pattern.
↓
VF / asystole / cardiac arrest.
33. Treatment Principles
Treatment of severe hyperkalaemia can be understood as four separate objectives:
1. Protect the heart.
2. Shift potassium into cells.
3. Remove potassium from the body.
4. Identify and treat the underlying cause.
This framework is more useful than simply memorising a drug list.
34. Intravenous Calcium – Protect the Heart
The original notes correctly include:
Intravenous calcium gluconate.
Calcium antagonises the adverse electrophysiological effects of hyperkalaemia on cardiac tissue.
Therefore:
IV CALCIUM → STABILISES THE CARDIAC MEMBRANE.
35. Calcium Does Not Lower Potassium
This is extremely important:
CALCIUM DOES NOT REDUCE THE SERUM POTASSIUM CONCENTRATION.
Its purpose is to:
Protect the myocardium while other treatments lower potassium.
Its effect begins rapidly but is temporary.
36. Insulin and Dextrose – Shift Potassium Into Cells
The original notes correctly include:
Intravenous insulin + dextrose/glucose.
Insulin stimulates:
Na⁺/K⁺-ATPase
and drives potassium:
From extracellular fluid → into cells.
Therefore:
INSULIN → RAPID TEMPORARY FALL IN SERUM K⁺.
Glucose is usually administered to reduce the risk of:
Hypoglycaemia.
Blood glucose requires monitoring after treatment.
37. Nebulised Salbutamol
The original notes correctly include:
Salbutamol nebulisers.
Salbutamol is a:
β₂-adrenergic agonist.
β₂ stimulation increases Na⁺/K⁺-ATPase activity and shifts potassium:
Into cells.
Therefore nebulised salbutamol can provide an additional temporary reduction in:
Serum K⁺.
It should not be relied upon as the sole treatment for severe hyperkalaemia.
38. Sodium Bicarbonate
Sodium bicarbonate is not routinely effective for every case of hyperkalaemia.
However, it may be considered in selected patients with significant:
Metabolic acidosis.
Its potassium-lowering effect is less predictable than insulin.
39. Removing Potassium From the Body
Treatments such as:
Insulin
and
Salbutamol
mainly redistribute potassium into cells.
They do not remove substantial potassium from the body.
Definitive potassium removal may require:
Renal excretion.
Gastrointestinal potassium binders.
or
Dialysis.
40. Furosemide
The original notes include:
Furosemide.
This loop diuretic can increase urinary potassium excretion if the patient has:
Adequate renal function and urine production.
Therefore it may be useful in selected patients, particularly when volume overload is also present.
It will be much less useful in:
Severe oliguric or anuric kidney failure.
41. Calcium Resonium
The original notes include:
Calcium resonium, or calcium polystyrene sulfonate.
This is a gastrointestinal:
Cation-exchange resin.
It binds potassium in the gastrointestinal tract and promotes its removal in stool.
However, it has a relatively slow and variable effect and is:
Not appropriate as the sole emergency treatment of life-threatening hyperkalaemia.
42. Newer Potassium Binders
Modern potassium-lowering options also include agents such as:
Sodium zirconium cyclosilicate
and
Patiromer.
Their role depends on the urgency and clinical context. They do not replace immediate cardiac protection and intracellular shifting therapy when severe ECG-toxic hyperkalaemia is present.
43. Dialysis
Dialysis directly removes potassium from the bloodstream.
It is particularly important when hyperkalaemia is:
Severe.
Refractory to medical treatment.
Recurrent after temporary intracellular shifting.
or associated with:
Severe kidney failure.
Therefore:
REFRACTORY SEVERE HYPERKALAEMIA = IMPORTANT INDICATION FOR URGENT DIALYSIS.
44. Emergency Treatment – Note Form
STEP 1 – Protect the heart
ECG changes / severe hyperkalaemia
↓
IV calcium gluconate
↓
Cardiac membrane stabilisation.
↓
Does NOT lower K⁺.
STEP 2 – Shift K⁺ into cells
IV insulin + glucose
and/or
Nebulised salbutamol.
↓
Serum K⁺ falls temporarily.
STEP 3 – Remove K⁺ from body
Depending on circumstances:
Loop diuretic if kidneys can excrete K⁺.
Potassium-binding therapy.
Dialysis when severe/refractory or renal failure prevents adequate excretion.
STEP 4 – Treat the cause
Stop or review potassium-raising drugs.
Treat AKI.
Correct appropriate acid–base disturbance.
Treat rhabdomyolysis/tumour lysis.
Treat adrenal insufficiency when present.
45. Causes – Note Form
SPURIOUS:
Haemolysed blood sample.
Traumatic venepuncture.
Marked thrombocytosis/leukocytosis.
EXCESS POTASSIUM:
IV potassium.
Oral potassium supplements.
Potassium-rich salt substitutes.
Especially dangerous with impaired renal function.
DECREASED EXCRETION:
AKI, especially oliguria/anuria.
Advanced CKD.
Addison disease.
Hypoaldosteronism.
DRUGS:
Spironolactone.
Amiloride.
ACE inhibitors.
ARBs.
NSAIDs.
Trimethoprim.
Heparin.
Tacrolimus/ciclosporin.
Potassium supplements.
REDISTRIBUTION / CELL RELEASE:
Acidosis.
Insulin deficiency/hyperosmolality.
Rhabdomyolysis.
Tumour lysis syndrome.
Acute digoxin toxicity.
46. Important Corrections to the Original Notes
The original classification of:
“Excessive intake” under “spurious”
should be corrected.
Haemolysis → pseudohyperkalaemia.
Excessive potassium administration → true hyperkalaemia.
The older terms:
“Acute renal failure”
and
“Chronic renal failure”
are better replaced with:
Acute kidney injury – AKI
and
Chronic kidney disease – CKD.
The ECG sequence in the original notes is useful, but remember:
ECG changes do not correlate perfectly with the serum potassium concentration.
A normal-looking ECG does not reliably exclude dangerous hyperkalaemia.
The original treatment list is broadly correct, but it is much easier to remember according to purpose:
CALCIUM → PROTECTS HEART.
INSULIN/GLUCOSE → SHIFTS K⁺ INTO CELLS.
SALBUTAMOL → SHIFTS K⁺ INTO CELLS.
FUROSEMIDE → INCREASES RENAL K⁺ EXCRETION IF KIDNEYS FUNCTION.
POTASSIUM BINDERS → REMOVE K⁺ THROUGH GI TRACT.
DIALYSIS → DIRECTLY REMOVES K⁺.
Key Clinical Pattern
For rapid recall:
HYPERKALAEMIA = THINK KIDNEYS + DRUGS + ALDOSTERONE + CELL BREAKDOWN/SHIFT.
AKI / CKD → ↓ K⁺ EXCRETION.
SPIRONOLACTONE / AMILORIDE / ACEi / ARB / NSAID → K⁺ RETENTION.
ADDISON / HYPOALDOSTERONISM → ↓ ALDOSTERONE → K⁺ RETENTION.
RHABDOMYOLYSIS / TUMOUR LYSIS → CELL BREAKDOWN → K⁺ RELEASE.
ACIDOSIS → K⁺ SHIFT OUT OF CELLS.
For the ECG:
PEAKED T → PR PROLONGATION → P WAVES FLATTEN/DISAPPEAR → QRS WIDENS → SINE WAVE → ARREST.
For emergency treatment, remember:
CALCIUM = PROTECT THE HEART.
INSULIN + GLUCOSE = SHIFT K⁺ INTO CELLS.
SALBUTAMOL = SHIFT K⁺ INTO CELLS.
DIURETIC/BINDER = REMOVE K⁺ WHEN APPROPRIATE.
DIALYSIS = DEFINITIVE RAPID REMOVAL WHEN SEVERE OR REFRACTORY.
- Published on
Medicine – Hypomagnesaemia
Hypomagnesaemia means an abnormally low concentration of magnesium in the blood. Magnesium is an important intracellular cation involved in neuromuscular function, cardiac electrical stability, enzyme activity, potassium regulation and calcium homeostasis.
Hypomagnesaemia is particularly important clinically because it frequently occurs together with:
Hypokalaemia – low K⁺
and
Hypocalcaemia – low Ca²⁺.
Severe deficiency can produce potentially life-threatening cardiac and neurological complications.
1. Normal Magnesium Physiology
Most magnesium in the body is located within:
Bone.
Muscle.
Other intracellular tissues.
Only a small proportion is present in extracellular fluid and measurable in serum.
Therefore, serum magnesium does not always perfectly reflect:
Total body magnesium stores.
2. Regulation of Magnesium
Magnesium balance depends mainly on:
Gastrointestinal absorption
and
Renal excretion.
The kidneys are particularly important because they can alter urinary magnesium excretion according to the body’s requirements.
Therefore hypomagnesaemia usually results from either:
Gastrointestinal magnesium loss
or
Renal magnesium wasting.
3. Hypomagnesaemia and Hypokalaemia
The original notes correctly state that hypomagnesaemia is commonly associated with:
Low K⁺.
Magnesium deficiency promotes renal potassium wasting.
Normally intracellular magnesium helps regulate potassium secretion through renal potassium channels.
When magnesium is deficient:
Renal K⁺ loss increases.
Therefore:
Hypomagnesaemia → renal potassium wasting → hypokalaemia.
4. Refractory Hypokalaemia
This relationship has an important clinical consequence.
If a patient has:
Hypokalaemia + hypomagnesaemia,
giving potassium alone may fail to correct the potassium concentration adequately.
Therefore:
REFRACTORY HYPOKALAEMIA → ALWAYS CONSIDER MAGNESIUM DEFICIENCY.
Magnesium replacement is often required before or alongside potassium replacement.
5. Hypomagnesaemia and Hypocalcaemia
Hypomagnesaemia can also produce:
Hypocalcaemia.
Severe magnesium deficiency interferes with:
Parathyroid hormone – PTH secretion
and can also cause:
Resistance to the actions of PTH.
The result is impaired calcium homeostasis.
Therefore:
Severe ↓ Mg²⁺ → ↓ PTH secretion/action → ↓ Ca²⁺.
6. Refractory Hypocalcaemia
As with potassium, calcium may be difficult to correct when significant magnesium deficiency remains untreated.
Therefore:
HYPOCALCAEMIA + HYPOKALAEMIA TOGETHER → CHECK MAGNESIUM.
This is a particularly useful clinical clue.
7. Neuromuscular Manifestations
Magnesium deficiency increases neuromuscular excitability.
Patients may develop:
Muscle cramps.
Muscle weakness.
Tremor.
Hyperreflexia.
Paraesthesiae.
Tetany.
Severe deficiency may cause:
Seizures – fits.
8. Paraesthesiae and Tetany
The original notes correctly include:
Paraesthesiae
and
Tetany.
Tetany may result from the combined effects of:
Magnesium deficiency
and associated:
Hypocalcaemia.
Patients may therefore develop tingling around the mouth or extremities, muscle spasms and increased neuromuscular irritability.
9. Seizures
Severe hypomagnesaemia can cause:
Seizures.
This occurs because magnesium plays an important role in stabilising neuronal membranes and regulating neuronal excitability.
Therefore severe magnesium deficiency should be considered among the metabolic causes of:
Acute seizures.
10. Cardiac Manifestations
One of the most important consequences of hypomagnesaemia is:
Cardiac electrical instability.
Magnesium participates in normal myocardial ion-channel function and cardiac repolarisation.
Deficiency therefore increases susceptibility to:
Cardiac arrhythmias.
11. Ventricular Arrhythmias
The original notes correctly associate hypomagnesaemia with:
Ventricular arrhythmias.
The risk becomes particularly important when hypomagnesaemia coexists with:
Hypokalaemia.
12. Torsades de Pointes
A particularly important association is:
Torsades de pointes.
This is a polymorphic ventricular tachycardia associated with:
QT prolongation.
Magnesium is therefore used therapeutically for torsades de pointes, even in some patients whose measured serum magnesium is not markedly reduced.
13. Causes of Hypomagnesaemia
The major mechanisms can be organised into:
Gastrointestinal loss or impaired absorption.
Renal magnesium loss.
Redistribution or metabolic causes.
Alcohol-related deficiency.
Drug-induced magnesium wasting.
14. Renal Magnesium Loss
The kidneys normally conserve magnesium when body stores are low.
If renal tubular handling is impaired, excessive magnesium is lost in:
Urine.
This produces:
Renal magnesium wasting.
Causes include certain medications, hypercalcaemia and inherited renal tubular disorders.
15. Gastrointestinal Loss
The gastrointestinal tract is another major source of magnesium loss.
Important causes include:
High-volume diarrhoea
and
Malabsorption.
16. High-Volume Diarrhoea
The original notes correctly include:
High-volume diarrhoea.
Prolonged diarrhoea causes direct gastrointestinal loss of magnesium.
It may simultaneously cause losses of:
Potassium.
Bicarbonate.
Water.
Therefore a patient with severe diarrhoea may develop:
Hypomagnesaemia + hypokalaemia + metabolic acidosis.
17. Malabsorption
Conditions causing chronic malabsorption can reduce intestinal magnesium absorption.
Examples include:
Coeliac disease.
Inflammatory bowel disease with significant intestinal involvement or resection.
Short-bowel syndrome.
Chronic severe diarrhoeal disorders.
Therefore chronic gastrointestinal disease may gradually deplete total body magnesium.
18. Hypercalcaemia
The original notes include:
Hypercalcaemia.
This is a recognised cause of renal magnesium wasting.
High calcium concentrations can interfere with magnesium reabsorption in the nephron, particularly in the:
Thick ascending limb of the loop of Henle.
Therefore:
Hypercalcaemia → ↑ renal Mg²⁺ loss → hypomagnesaemia.
19. Diabetic Ketoacidosis
The original notes correctly include:
Diabetic ketoacidosis – DKA.
Patients with DKA often have significant total-body electrolyte depletion due to:
Osmotic diuresis.
This causes urinary losses of:
Water.
Potassium.
Magnesium.
Phosphate.
20. Magnesium in DKA
Even when the initial serum magnesium is not dramatically low, the patient’s:
Total body magnesium stores may be depleted.
Treatment with insulin and correction of the metabolic disturbance can alter extracellular concentrations further.
Therefore electrolytes require careful monitoring during DKA treatment.
21. Alcohol
The original notes correctly identify:
Alcohol
as an important cause.
Chronic alcohol use can produce magnesium deficiency through several mechanisms.
These include:
Poor nutritional intake.
Gastrointestinal losses.
Renal magnesium wasting.
Associated pancreatitis or diarrhoea may contribute further.
22. Alcohol and Multiple Electrolyte Abnormalities
Patients with chronic heavy alcohol exposure may simultaneously develop:
Hypomagnesaemia.
Hypokalaemia.
Hypophosphataemia.
Other nutritional deficiencies may also coexist.
Therefore magnesium should be checked in patients with alcohol-related illness and unexplained electrolyte abnormalities.
23. Drug-Induced Hypomagnesaemia
Several medications can cause magnesium depletion by increasing:
Renal magnesium excretion
or reducing:
Intestinal magnesium absorption.
The original notes correctly include:
Loop/thiazide diuretics.
Aminoglycosides.
Cisplatin.
Ciclosporin.
24. Loop Diuretics
Loop diuretics such as:
Furosemide
reduce sodium, potassium and chloride reabsorption in the thick ascending limb.
They can also increase urinary loss of:
Magnesium
and
Calcium.
Therefore prolonged or intensive loop-diuretic treatment may contribute to:
Hypomagnesaemia.
25. Thiazide Diuretics
Thiazide diuretics can also increase:
Renal magnesium loss.
Chronic therapy may therefore produce:
Hypomagnesaemia, particularly in susceptible patients.
Remember the calcium distinction:
Loop diuretics → ↑ urinary Ca²⁺.
Thiazides → ↓ urinary Ca²⁺.
But both can contribute to:
Magnesium loss.
26. Aminoglycosides
Aminoglycoside antibiotics can cause renal tubular toxicity.
Examples include:
Gentamicin.
Amikacin.
Tobramycin.
Tubular injury can impair magnesium reabsorption and produce:
Renal magnesium wasting.
27. Cisplatin
The chemotherapy agent:
Cisplatin
is an important cause of hypomagnesaemia.
It can damage renal tubular cells and produce persistent:
Renal magnesium wasting.
The magnesium deficiency may sometimes persist even after cisplatin treatment has finished.
28. Ciclosporin
Ciclosporin can also promote renal magnesium loss.
This is particularly relevant in patients receiving:
Immunosuppressive therapy, including transplant recipients.
Other calcineurin inhibitors, particularly:
Tacrolimus,
can have a similar effect.
29. Proton-Pump Inhibitors – Important Additional Cause
A major modern addition to the original list is:
Proton-pump inhibitors – PPIs.
Long-term PPI therapy can occasionally cause significant hypomagnesaemia by impairing:
Intestinal magnesium absorption.
Examples include:
Omeprazole.
Esomeprazole.
Pantoprazole.
Therefore unexplained persistent hypomagnesaemia should prompt review of:
PPI use.
30. Inherited Renal Causes
Certain inherited renal tubular disorders also produce magnesium loss.
An important example is:
Gitelman syndrome.
Gitelman syndrome typically causes:
Hypokalaemia.
Metabolic alkalosis.
Hypomagnesaemia.
Hypocalciuria.
31. Gitelman Syndrome
The renal defect resembles chronic exposure to a:
Thiazide diuretic.
Therefore:
GITELMAN → LOW K⁺ + LOW Mg²⁺ + METABOLIC ALKALOSIS + LOW URINARY Ca²⁺.
This is a useful examination pattern.
32. Clinical Features – Note Form
Cardiac:
Ventricular arrhythmias.
QT abnormalities.
Torsades de pointes.
Neurological:
Seizures.
Tremor.
Hyperreflexia.
Neuromuscular:
Tetany.
Muscle cramps.
Paraesthesiae.
Weakness.
Associated biochemical abnormalities:
Hypokalaemia.
Hypocalcaemia.
33. Causes – Note Form
Gastrointestinal loss:
High-volume diarrhoea.
Malabsorption.
Short-bowel states.
Renal loss:
Renal tubular disorders.
Hypercalcaemia.
Metabolic:
DKA with osmotic diuresis.
Alcohol:
Poor intake + GI loss + renal wasting.
Drugs:
Loop diuretics.
Thiazide diuretics.
Aminoglycosides.
Cisplatin.
Ciclosporin.
Tacrolimus.
Long-term PPIs.
34. Investigation
When hypomagnesaemia is identified, assessment should include:
Serum magnesium.
Potassium.
Calcium.
Renal function.
Other electrolytes may also be appropriate depending on the clinical situation.
35. Distinguishing Renal From Gastrointestinal Loss
If the cause is uncertain, urinary magnesium measurements can help determine whether the kidneys are appropriately conserving magnesium.
Conceptually:
Low urinary Mg²⁺ in hypomagnesaemia → kidneys are conserving magnesium → consider GI loss or poor intake.
In contrast:
Inappropriately high urinary Mg²⁺ → renal magnesium wasting.
This distinction can help identify the underlying mechanism.
36. Treatment
Treatment depends on:
Severity.
Symptoms.
Underlying cause.
Renal function.
Mild or asymptomatic deficiency can often be treated with:
Oral magnesium replacement.
37. Severe or Symptomatic Hypomagnesaemia
Severe deficiency associated with:
Seizures.
Tetany.
Significant ventricular arrhythmias.
may require:
Intravenous magnesium, commonly magnesium sulfate, with appropriate monitoring.
The underlying cause should also be corrected.
38. Correct Associated Electrolyte Abnormalities
If the patient also has:
Hypokalaemia
or
Hypocalcaemia,
magnesium deficiency should be corrected because these abnormalities may otherwise remain:
Refractory to treatment.
Therefore:
LOW Mg²⁺ + LOW K⁺ → REPLACE Mg²⁺ AS WELL AS K⁺.
39. Important Clarifications to the Original Notes
The statement:
“Usually associated with low Ca²⁺ and low K⁺”
is useful clinically, although not every patient will have both abnormalities.
The mechanisms are different:
Low Mg²⁺ → renal K⁺ wasting → hypokalaemia.
Severe low Mg²⁺ → impaired PTH secretion/action → hypocalcaemia.
The listed manifestations:
Ventricular arrhythmias, fits, tetany and paraesthesiae
are correct.
A particularly important cardiac complication to remember is:
TORSADES DE POINTES.
The original causes are also appropriate:
Renal loss.
High-volume diarrhoea.
Malabsorption.
Hypercalcaemia.
DKA.
Alcohol.
Loop/thiazide diuretics.
Aminoglycosides.
Cisplatin.
Ciclosporin.
Important modern additions include:
PPIs, tacrolimus and inherited renal tubular disorders such as Gitelman syndrome.
Key Clinical Pattern
For rapid recall:
HYPOMAGNESAEMIA → NEUROMUSCULAR EXCITABILITY + CARDIAC INSTABILITY.
Think:
BRAIN → SEIZURES.
NERVES/MUSCLES → PARAESTHESIAE + TETANY + TREMOR.
HEART → VENTRICULAR ARRHYTHMIAS + TORSADES.
ELECTROLYTES → ↓ K⁺ + ↓ Ca²⁺.
For the mechanism:
LOW Mg²⁺ → RENAL K⁺ WASTING → REFRACTORY HYPOKALAEMIA.
SEVERE LOW Mg²⁺ → ↓ PTH SECRETION/ACTION → HYPOCALCAEMIA.
For causes:
GI LOSS → DIARRHOEA / MALABSORPTION.
RENAL LOSS → DIURETICS / AMINOGLYCOSIDES / CISPLATIN / CALCINEURIN INHIBITORS / HYPERCALCAEMIA.
METABOLIC → DKA.
ALCOHOL → POOR INTAKE + GI LOSS + RENAL WASTING.
DRUG ABSORPTION PROBLEM → LONG-TERM PPI USE.
And the high-yield clinical rule is:
HYPOKALAEMIA THAT WILL NOT CORRECT → CHECK AND CORRECT MAGNESIUM.
- Published on
Medicine – Copper Metabolism and Wilson Disease
Wilson disease is an inherited disorder of copper metabolism in which the body cannot excrete copper normally into bile. Copper therefore progressively accumulates, particularly in the liver, brain, cornea and other tissues, producing hepatic, neurological, psychiatric and systemic manifestations.
The disorder is inherited in an:
Autosomal recessive – AR pattern.
1. Normal Copper Metabolism
Copper is an essential trace element obtained from the diet. After intestinal absorption, copper is transported to the:
Liver.
The liver has a central role in incorporating copper into proteins and eliminating excess copper from the body.
2. Ceruloplasmin
The original notes state that copper normally binds to a globulin to form:
Ceruloplasmin.
This is broadly correct, although the mechanism can be described more precisely.
Ceruloplasmin is a copper-containing plasma protein synthesised in the:
Liver.
Most circulating copper is carried bound to:
Ceruloplasmin.
3. Copper Excretion
The original notes correctly state that copper is predominantly excreted through:
Bile.
The liver secretes excess copper into bile, which passes into the intestine and is eventually eliminated in:
Faeces.
Urinary copper excretion is normally relatively small.
Therefore:
BILE IS THE MAJOR ROUTE OF COPPER EXCRETION.
4. Wilson Disease
Wilson disease results from pathogenic variants in the:
ATP7B gene.
ATP7B is located on:
Chromosome 13.
It encodes a copper-transporting ATPase that is particularly important in hepatocytes.
5. Inheritance
Wilson disease is:
Autosomal recessive.
Therefore an affected individual usually inherits a pathogenic ATP7B variant from:
Each parent.
Siblings of an affected patient may therefore require appropriate screening.
6. ATP7B Function
ATP7B normally has two particularly important functions:
It helps incorporate copper into ceruloplasmin.
and
It facilitates excretion of excess copper into bile.
When ATP7B function is defective, both processes are impaired.
7. Pathophysiology
The basic mechanism is:
ATP7B defect
↓
↓ biliary copper excretion
↓
Copper accumulates in hepatocytes
↓
Hepatic injury
↓
Copper eventually enters the circulation and deposits in other organs
↓
Brain + cornea + kidneys + joints + other tissues affected.
8. Important Correction About Ceruloplasmin
The original statement:
“Abnormality of ceruloplasmin formation and biliary excretion”
is broadly useful, but Wilson disease is fundamentally caused by:
Defective ATP7B-mediated copper transport.
The major problem responsible for copper overload is:
Impaired biliary copper excretion.
Ceruloplasmin is typically low because copper is not incorporated normally into apoceruloplasmin, which is then degraded more rapidly.
9. Liver Disease
The liver is often one of the first organs affected.
Wilson disease can produce a wide spectrum of hepatic disease, including:
Asymptomatic elevation of liver enzymes.
Acute hepatitis.
Chronic hepatitis.
Fibrosis.
Cirrhosis.
Acute liver failure.
Therefore Wilson disease should be considered particularly in a:
Young person with otherwise unexplained liver disease.
10. Acute Liver Failure
Wilson disease can occasionally present with:
Fulminant/acute liver failure.
This may be accompanied by:
Coombs-negative haemolytic anaemia.
Jaundice.
Coagulopathy.
Renal dysfunction.
This is a medical emergency.
11. Kayser–Fleischer Rings
The original notes correctly identify:
Kayser–Fleischer rings – KF rings
as a classic feature.
They result from copper deposition in:
Descemet membrane of the cornea.
12. Appearance of Kayser–Fleischer Rings
KF rings appear as:
Brownish, golden or greenish-brown rings
around the peripheral cornea.
They are best detected using:
Slit-lamp examination.
13. Significance of Kayser–Fleischer Rings
KF rings are particularly common in patients with:
Neurological Wilson disease.
However, an important point is:
ABSENCE OF KF RINGS DOES NOT EXCLUDE WILSON DISEASE.
They may be absent, particularly in patients presenting predominantly with hepatic disease.
14. Neurological Manifestations
Copper deposition in the brain, particularly the:
Basal ganglia,
can produce numerous neurological abnormalities.
Possible features include:
Tremor.
Dysarthria.
Dystonia.
Parkinsonian features.
Rigidity.
Bradykinesia.
Ataxia or impaired coordination.
Abnormal involuntary movements.
15. Tremor
A classic neurological manifestation is tremor.
A characteristic but not universal description is:
Wing-beating tremor.
This is a coarse proximal tremor that may become prominent when the arms are held out.
16. Psychiatric Manifestations
Psychiatric and behavioural changes are also important.
Patients may develop:
Personality change.
Irritability.
Depression.
Anxiety.
Behavioural deterioration.
Psychosis in some cases.
Declining school or work performance.
Therefore Wilson disease can initially appear to be a primary psychiatric or neurological disorder.
17. Arthropathy
The original notes correctly include:
Arthropathy.
Joint manifestations may include:
Joint pain.
Premature degenerative changes.
Arthritis-like symptoms.
Large joints such as the knees may be affected.
18. Haemolytic Anaemia
Wilson disease can cause:
Coombs-negative intravascular haemolytic anaemia.
This is particularly important during acute hepatic deterioration.
When damaged hepatocytes suddenly release large amounts of copper into the circulation, free copper can damage:
Red-cell membranes.
This produces:
Haemolysis.
19. Haemolysis – Note Form
Hepatocyte injury
↓
Sudden release of copper
↓
Free circulating copper rises
↓
RBC membrane injury
↓
Coombs-negative intravascular haemolysis.
Therefore:
YOUNG PATIENT + LIVER FAILURE + COOMBS-NEGATIVE HAEMOLYSIS → THINK WILSON DISEASE.
20. Other Manifestations
Copper accumulation can affect other organs.
Possible manifestations include:
Renal tubular dysfunction.
Nephrolithiasis.
Skeletal abnormalities.
Cardiac involvement, although less common.
The clinical presentation is highly variable.
21. Diagnosis of Wilson Disease
The diagnosis should not usually depend on one test alone.
Assessment combines:
Serum ceruloplasmin.
Urinary copper excretion.
Slit-lamp examination for KF rings.
Serum copper assessment in appropriate contexts.
Liver copper measurement when needed.
ATP7B genetic testing.
22. Serum Ceruloplasmin
The original notes correctly state:
Ceruloplasmin is usually low.
This is an important clue to Wilson disease.
However:
Low ceruloplasmin alone does not establish the diagnosis.
It can also occur in other conditions.
Conversely, some patients with Wilson disease may have ceruloplasmin values that are not markedly reduced.
23. Serum Copper – Important Paradox
A potentially confusing feature is that:
Total serum copper may be low
because most circulating copper is normally bound to ceruloplasmin, and ceruloplasmin is reduced.
However, the biologically important:
Non-ceruloplasmin-bound copper
may be increased.
Therefore:
LOW TOTAL SERUM COPPER DOES NOT EXCLUDE COPPER OVERLOAD IN WILSON DISEASE.
The problem is abnormal tissue accumulation and increased toxic circulating copper, not simply the total serum copper concentration.
24. Urinary Copper
The original notes correctly include:
High urinary copper.
Twenty-four-hour urinary copper excretion is typically increased because excess non-ceruloplasmin-bound copper becomes available for renal excretion.
Therefore:
WILSON DISEASE → ↑ URINARY COPPER.
25. Liver Biopsy
The original notes include:
Liver biopsy.
When required, hepatic copper concentration can be measured from biopsy tissue.
A markedly elevated hepatic copper concentration strongly supports:
Wilson disease.
However, liver biopsy is not necessary in every patient if the diagnosis can be established through biochemical, ophthalmological and genetic findings.
26. Genetic Testing
Modern evaluation may include:
ATP7B genetic testing.
Identification of pathogenic variants on both alleles can strongly support or establish the diagnosis in the appropriate clinical context.
Genetic testing is also useful for:
Family screening.
27. Brain Imaging
In patients with neurological disease, MRI may demonstrate abnormalities involving structures such as the:
Basal ganglia.
However, MRI findings are supportive rather than diagnostic by themselves.
28. Treatment
Wilson disease requires:
Lifelong management.
Treatment aims to reduce toxic copper accumulation and prevent further deposition.
Major approaches include:
Copper chelation.
Reduction of intestinal copper absorption.
Liver transplantation in selected severe disease.
29. Penicillamine
The original notes correctly identify:
D-penicillamine
as a copper-chelating drug.
It binds copper and promotes its elimination, particularly through:
Urine.
Therefore:
PENICILLAMINE + COPPER → CHELATED COPPER → ↑ URINARY EXCRETION.
30. Adverse Effects of Penicillamine
Penicillamine can cause significant adverse effects, including:
Bone-marrow suppression.
Proteinuria and renal toxicity.
Skin reactions.
Autoimmune complications.
Neurological symptoms can sometimes worsen after treatment initiation, so specialist monitoring is important.
31. Trientine
An important alternative copper chelator is:
Trientine.
It can be used as an alternative to penicillamine in appropriate patients and also increases:
Urinary copper excretion.
Modern Wilson disease management is therefore not limited to penicillamine alone.
32. Zinc Therapy
Zinc salts provide another treatment strategy.
Zinc reduces intestinal copper absorption by inducing intestinal:
Metallothionein.
Metallothionein binds copper within enterocytes.
The copper is then lost when the intestinal cells are shed.
Therefore:
ZINC → ↓ INTESTINAL COPPER ABSORPTION.
Zinc may be used in selected patients, including maintenance therapy depending on the clinical situation.
33. Liver Transplantation
The original notes correctly include:
Liver transplantation.
It is particularly important in:
Acute liver failure due to Wilson disease
and selected patients with:
Decompensated end-stage liver disease.
34. Why Liver Transplantation Is Particularly Effective
The liver contains the major defect in ATP7B-mediated copper handling.
Replacing the liver therefore restores:
Normal hepatic copper metabolism and biliary copper excretion.
Thus transplantation can effectively correct the underlying metabolic defect.
35. Dietary Considerations
During treatment, patients may be advised to avoid excessive intake of particularly copper-rich foods, especially early in therapy.
Examples can include:
Liver and organ meats.
Shellfish.
Some nuts and chocolate.
However, dietary restriction alone is:
Not adequate treatment for established Wilson disease.
36. Wilson Disease – Note Form
Inheritance:
Autosomal recessive.
Gene:
ATP7B.
Chromosome 13.
Normal physiology:
Copper transported to liver.
↓
Copper incorporated into ceruloplasmin.
↓
Excess copper excreted in bile.
Wilson disease:
ATP7B defect.
↓
↓ Copper incorporation into ceruloplasmin.
- ●
↓ Biliary copper excretion.
↓
Copper accumulation.
↓
Liver + brain + cornea + other organs.
37. Clinical Features – Note Form
Liver:
Acute hepatitis.
Chronic hepatitis.
Cirrhosis.
Acute liver failure.
Eye:
Kayser–Fleischer rings.
Copper deposited in Descemet membrane.
CNS:
Tremor.
Dystonia.
Dysarthria.
Parkinsonian features.
Movement abnormalities.
Psychiatric:
Personality change.
Depression.
Behavioural disturbance.
Psychosis in some cases.
Joints:
Arthropathy.
Blood:
Coombs-negative haemolytic anaemia.
38. Diagnosis – Note Form
Ceruloplasmin:
Usually ↓.
24-hour urinary copper:
↑.
Kayser–Fleischer rings:
Detected by slit lamp.
Liver copper:
↑ when measured.
ATP7B genetic testing:
Supports/confirms diagnosis in appropriate circumstances.
39. Treatment – Note Form
Penicillamine:
Copper chelator.
↓
↑ urinary copper excretion.
Trientine:
Alternative copper chelator.
↓
↑ urinary copper excretion.
Zinc:
↓ intestinal copper absorption.
Liver transplantation:
Acute liver failure or selected severe/decompensated liver disease.
↓
Corrects hepatic metabolic defect.
40. Important Corrections to the Original Notes
The original statement:
“Copper usually binds to globulin to form ceruloplasmin”
is better expressed as:
CERULOPLASMIN IS A COPPER-CONTAINING PROTEIN SYNTHESISED BY THE LIVER AND CARRIES MOST CIRCULATING COPPER.
The original statement:
“Abnormality of ceruloplasmin formation and biliary excretion”
is broadly correct, but the fundamental defect is:
ATP7B MUTATION → IMPAIRED COPPER INCORPORATION INTO CERULOPLASMIN + IMPAIRED BILIARY COPPER EXCRETION.
The impaired biliary excretion is particularly important for:
Progressive tissue copper accumulation.
Low ceruloplasmin is an important diagnostic clue but is:
Not diagnostic by itself.
High urinary copper is an important feature.
Liver biopsy can measure hepatic copper but is:
Not mandatory in every patient.
Treatment is broader than:
“Penicillamine + liver transplantation.”
Modern management may include:
PENICILLAMINE, TRIENTINE, ZINC, AND LIVER TRANSPLANTATION WHEN INDICATED.
Key Clinical Pattern
For rapid recall:
WILSON DISEASE = AR ATP7B DEFECT ON CHROMOSOME 13.
ATP7B DEFECT → ↓ BILIARY COPPER EXCRETION → COPPER ACCUMULATION.
Think:
LIVER → HEPATITIS / CIRRHOSIS / ACUTE LIVER FAILURE.
EYE → KAYSER–FLEISCHER RINGS.
BRAIN → TREMOR / DYSTONIA / PARKINSONISM / PSYCHIATRIC CHANGE.
JOINTS → ARTHROPATHY.
BLOOD → COOMBS-NEGATIVE HAEMOLYTIC ANAEMIA.
For diagnosis:
↓ CERULOPLASMIN + ↑ URINARY COPPER + KF RINGS ± ↑ HEPATIC COPPER + ATP7B TESTING.
For treatment:
CHELATE COPPER WITH PENICILLAMINE OR TRIENTINE → REDUCE ABSORPTION WITH ZINC → TRANSPLANT FOR SEVERE LIVER FAILURE.
- Published on
Orthopaedic Surgery - Hand Anatomy and Examination
Basics
The hand is a highly specialized organ that provides strength, precision, sensation, grasp, and fine motor control, allowing complex activities ranging from heavy manual work to delicate manipulation.
Anatomically, the hand can be divided into volar (palmar) and dorsal surfaces.
Volar Anatomy
The volar aspect contains many of the major structures responsible for hand function, including the digital nerves, major vascular structures, flexor tendons, and intrinsic muscles.
Because these structures are closely packed together, even relatively small palmar lacerations may injure several important tissues simultaneously.
Bony Anatomy
The hand and wrist contain a complex arrangement of bones.
There are:
8 carpal bones, 5 metacarpals, and 14 phalanges.
Each finger contains a proximal, middle, and distal phalanx.
The thumb has only two phalanges: proximal and distal.
History
A thorough history should precede the physical examination.
Important information includes:
Hand dominance, occupation, previous hand injuries or operations, mechanism of trauma, duration of symptoms, and location and character of pain.
Functional complaints such as weakness, loss of grip, numbness, locking, instability, or difficulty with specific activities should also be documented.
General Examination Principles
Understanding normal hand anatomy and biomechanics is essential for identifying injury.
The examiner should use a consistent, systematic examination sequence so that important structures are not overlooked.
The opposite hand provides an extremely useful comparison with the patient’s normal anatomy, strength, motion, and joint laxity.
Inspection
The hand should first be observed at rest.
Resting Posture
The natural posture of the fingers should be assessed.
Abnormal finger position may indicate tendon rupture, nerve injury, fracture, dislocation, or joint contracture.
The normal flexor cascade should also be observed.
Deformity
The examiner should identify any gross angular, rotational, or joint deformity.
Rotational malalignment may become more obvious when the patient makes a fist.
Soft-Tissue Changes
Look for:
Swelling, bruising, erythema, wounds, scars, masses, muscle wasting, and skin abnormalities.
Nail and Fingertip Examination
The nail plate, nail folds, pulp, and surrounding soft tissues should be inspected for:
Subungual hematoma, nail-bed injury, infection, fingertip trauma, vascular compromise, or deformity.
Vascular Examination
Adequate perfusion should be confirmed in the hand and each individual digit.
Radial and Ulnar Arteries
The radial and ulnar arteries should be palpated at the wrist.
Doppler examination can be used if pulses are difficult to detect.
Digital Arteries
The digital arteries can be assessed with handheld Doppler when vascular injury is suspected.
Capillary Refill
Capillary refill should be tested in each finger.
Normal refill is generally less than approximately 2 seconds in a warm, well-perfused hand.
Additional Perfusion Assessment
When necessary, finger temperature and pulse oximetry may provide additional information about digital perfusion.
These measurements are particularly useful when vascular compromise is subtle.
Allen Test
The Allen test assesses patency of the radial and ulnar arteries and the completeness of the palmar arterial arch.
The patient repeatedly opens and closes the hand while the examiner compresses both the radial and ulnar arteries.
The hand is then opened and one artery is released.
Rapid return of color indicates adequate flow through that artery and the palmar arch.
The test is then repeated for the opposite artery.
Delayed or absent reperfusion suggests arterial obstruction or incomplete collateral circulation.
Neurologic Examination
Neurologic assessment should include both sensory and motor testing.
The median, ulnar, and radial nerves should be evaluated systematically.
Sensory Examination
Sensation can initially be tested with light touch.
Two-point discrimination provides a more detailed evaluation of digital nerve function.
Two-Point Discrimination
Normal static two-point discrimination at the fingertip is generally approximately 6 mm or less, while moving two-point discrimination is normally somewhat finer.
The result should be compared with the opposite hand and adjacent digits.
A bent paperclip or formal discriminator can be used when dedicated instruments are unavailable.
Motor Examination
Both the extrinsic muscles, originating in the forearm, and the intrinsic muscles, originating within the hand, should be tested.
Extrinsic Flexors
The flexor digitorum superficialis and flexor digitorum profundus tendons should be tested individually in each finger.
Flexor Digitorum Profundus
To test the FDP, hold the PIP joint in extension and ask the patient to flex the DIP joint.
Active DIP flexion indicates continuity of the profundus tendon.
Flexor Digitorum Superficialis
To isolate the FDS, hold the other fingers in extension and ask the patient to flex the finger being tested at the PIP joint.
Extrinsic Extensors
Finger extension at the MCP joints should be tested individually.
Thumb extension should also be assessed.
Weakness may reflect tendon injury or radial nerve dysfunction proximal to the hand.
Intrinsic Muscles
The intrinsic muscles can be assessed by asking the patient to flex the MCP joints while extending the interphalangeal joints.
Finger abduction and adduction should also be tested with the MCP joints extended.
Asking the patient to cross adjacent fingers can further assess intrinsic muscle function.
Median Nerve
Sensory Examination
Median nerve sensation should be tested over the palmar aspect of the thumb, index finger, middle finger, and radial half of the ring finger.
Thenar Eminence
Sensation over the thenar eminence is supplied by the palmar cutaneous branch of the median nerve, which branches proximal to the carpal tunnel.
This area should be tested separately.
Preserved thenar sensation despite numbness in the median-innervated digits can support localization of compression to the carpal tunnel.
Motor Examination
Palmar abduction of the thumb assesses the abductor pollicis brevis and is an important test of recurrent motor branch function of the median nerve.
Ulnar Nerve
Sensory Examination
Sensation should be tested over the little finger and ulnar half of the ring finger, including the volar fingertip.
Motor Examination
The ulnar nerve supplies most of the intrinsic muscles of the hand.
Motor function can be tested by asking the patient to abduct and adduct the fingers or cross the fingers.
Radial Nerve
Sensory Examination
Radial nerve sensation is best assessed over the dorsal first web space.
Motor Examination
The radial nerve does not provide meaningful intrinsic motor innervation within the hand itself.
Motor function is assessed through muscles in the forearm by testing wrist extension, MCP joint extension of the fingers, and thumb extension.
Bones, Tendons, and Ligaments
Every bone and major joint should be palpated systematically when trauma or localized pain is present.
Range of Motion
Both active and passive range of motion should be assessed.
Approximate normal values include:
Thumb IP joint: approximately 0–80° of flexion.
Thumb MCP joint: approximately 0–50° of flexion.
Finger DIP joints: approximately 0–70 to 90°.
Finger PIP joints: approximately 0–100° or slightly greater.
Finger MCP joints: approximately 0–90°.
Wrist flexion: approximately 80°.
Wrist extension: approximately 70°.
Normal motion varies among individuals, so comparison with the opposite side is valuable.
Joint Examination
Each joint should be assessed for:
Tenderness, swelling, effusion, bogginess, instability, crepitus, loss of motion, or hypermobility.
Collateral Ligaments
Excessive side-to-side laxity may indicate injury to a collateral ligament.
Stress testing should be performed carefully and compared with the opposite side.
Important Wrist Structures
Two common sources of wrist pathology are the scapholunate ligament and the triangular fibrocartilage complex (TFCC).
Scapholunate Ligament
The scapholunate interval should be palpated dorsally for tenderness, particularly after wrist trauma.
TFCC
The TFCC lies on the ulnar side of the wrist and contributes to distal radioulnar and ulnocarpal stability.
Tenderness in this region may indicate a TFCC injury.
Special Tests
Tinel Sign at the Carpal Tunnel
Percussion over the median nerve at the volar wrist may produce tingling, numbness, or electric sensations in the median nerve distribution.
A positive test supports median nerve irritation and may be seen in carpal tunnel syndrome.
Flexion-Compression Test
The examiner applies direct pressure over the carpal tunnel while the wrist is held in flexion.
Reproduction of numbness, tingling, or pain in the median distribution within approximately 30 seconds supports the diagnosis of carpal tunnel syndrome.
Phalen Test
The patient holds the wrists in maximal flexion, usually by placing the dorsal surfaces of the hands together.
Development of paresthesias in the median nerve distribution within approximately 60 seconds is considered a positive test.
Wrist Aspiration
Wrist aspiration may be performed when infection, crystal arthropathy, hemarthrosis, or another joint process is suspected.
Dorsal Approach
A common dorsal entry point is between the third extensor compartment, containing extensor pollicis longus, and the fourth compartment, containing extensor digitorum communis and extensor indicis proprius.
Lister’s tubercle can be used as a palpable landmark.
The radiocarpal joint is entered just distal to this region, with slight wrist flexion facilitating access.
Eichhoff Test
The Eichhoff maneuver is frequently, although inaccurately, referred to as the Finkelstein test.
The patient places the thumb within the fist, and the examiner then passively deviates the wrist toward the ulna.
Pain over the first dorsal extensor compartment, containing the abductor pollicis longus and extensor pollicis brevis, supports the diagnosis of de Quervain tenosynovitis.
The true Finkelstein maneuver is performed somewhat differently, but both tests stress the first extensor compartment.
Thumb CMC Grind Test
The thumb carpometacarpal joint is assessed by applying axial compression through the thumb metacarpal while rotating or grinding the joint.
Reproduction of pain, particularly with crepitus, is consistent with trapeziometacarpal or thumb CMC osteoarthritis.
Imaging
Plain Radiographs
The standard hand radiographic series includes:
AP or PA, oblique, and lateral views.
These films help identify fractures, dislocations, joint-space abnormalities, malalignment, and degenerative changes.
Lateral View
For evaluation of individual digits, the fingers may be splayed or separated on the lateral projection to prevent overlap and allow clearer visualization of each phalanx and joint.
General Examination Approach
A complete hand assessment should proceed systematically through:
Inspection, vascular examination, sensory testing, motor testing, tendon assessment, joint range of motion, ligament stability, palpation, special tests, and appropriate imaging.
Because the structures of the hand are small and closely related, comparison with the opposite hand and careful documentation are especially important for detecting subtle abnormalities.
- Published on
.
Orthopaedic Surgery - Hamstring Strain
⸻
Basics
The hamstrings are a group of long muscles located in the posterior thigh. They extend from the pelvis toward the knee and play an important role in hip extension, knee flexion, gait, sprinting, and deceleration.
A hamstring strain is a stretch-induced or forceful contraction injury of the muscle-tendon unit.
The injury commonly occurs when the hamstrings are required to change rapidly from controlling limb motion eccentrically to generating force concentrically, particularly during sudden acceleration or deceleration.
⸻
Mechanism
Hamstring strains frequently occur during quick starts, sudden stops, sprinting, jumping, or other explosive movements that produce a powerful contraction while the muscle is lengthened.
⸻
Classification
Hamstring strains are traditionally divided into three grades according to severity.
⸻
Mild Strain
A mild strain produces pain and muscle spasm without a substantial structural tear.
There is minimal loss of strength and usually only mild functional limitation.
⸻
Moderate Strain
A moderate injury involves partial tearing of muscle fibers.
Pain is more pronounced, and measurable weakness and functional limitation are present.
⸻
Severe Strain
A severe injury represents a complete or near-complete tear of the muscle or tendon, sometimes including avulsion from its bony attachment.
Marked weakness and immediate loss of function are typical.
⸻
Limitations of Grading
Traditional strain grading provides a useful description of injury severity, but clinical classification systems do not consistently predict the exact time required for return to sport.
⸻
Prevention
Prevention programs focus on improving hamstring strength, flexibility, fatigue resistance, and neuromuscular control.
⸻
Stretching
Regular hamstring stretching may be beneficial, particularly as part of a structured conditioning program.
Stretching should be performed carefully when the muscles are fatigued.
⸻
Conditioning
Anaerobic interval training and sport-specific drills can improve the ability of the hamstrings to tolerate repeated high-speed loading.
⸻
Strengthening
Eccentric hamstring strengthening is particularly important because the hamstrings undergo substantial eccentric loading during sprinting and deceleration.
⸻
Epidemiology
Hamstring strains are among the most common injuries encountered in athletes.
They are particularly associated with sports requiring sprinting, jumping, kicking, sudden acceleration, and ballistic lower-extremity movements.
⸻
Frequency
Hamstring injuries have been reported to account for a substantial proportion of sports-related injuries, reaching approximately 29% in some athletic populations.
They account for approximately 12% of injuries among professional football players in some series.
⸻
Associated Sports
Activities commonly associated with hamstring injury include running, football, skiing, dancing, skating, jumping, and weight lifting.
⸻
Recurrence
Recurrence is a major clinical problem.
Approximately one-third of hamstring injuries may recur, particularly when return to sport occurs before full recovery of strength and flexibility.
⸻
Risk Factors
Important risk factors include:
Increasing age, previous hamstring injury, muscle weakness, imbalance between quadriceps and hamstring strength, reduced lower-extremity flexibility, impaired trunk or core stability, fatigue, and dehydration.
The strongest predictor of future hamstring injury is often a previous hamstring strain.
⸻
Anatomy and Pathophysiology
The principal hamstring muscles are the biceps femoris, semitendinosus, and semimembranosus.
⸻
Proximal Origin
The semitendinosus, semimembranosus, and long head of the biceps femoris originate from the ischial tuberosity.
The short head of the biceps femoris originates from the posterior femur rather than the pelvis.
⸻
Distal Insertions
The biceps femoris inserts primarily on the fibular head.
The semitendinosus inserts medially on the proximal tibia as part of the pes anserinus, while the semimembranosus inserts on the posteromedial proximal tibia.
⸻
Function
The hamstrings flex the knee and contribute to hip extension.
During running and gait, they contract eccentrically to decelerate knee extension and absorb kinetic energy.
⸻
Common Site of Injury
Muscle strain most often occurs near a musculotendinous junction, frequently involving the biceps femoris, especially during high-speed running.
⸻
Pediatric and Adolescent Considerations
In children and adolescents, the tendon may be stronger than the immature apophysis.
A forceful hamstring contraction can therefore produce an ischial tuberosity avulsion fracture rather than a purely tendinous injury.
⸻
Adult Considerations
In adults, the same mechanism may produce a partial or complete proximal hamstring tendon avulsion.
⸻
Etiology
Hamstring strains usually occur when the muscle is rapidly lengthened while simultaneously generating substantial force.
⸻
Predisposing Factors
Predisposing factors include:
Poor flexibility, inadequate warm-up, fatigue, dehydration, muscle weakness, impaired coordination between opposing muscle groups, and quadriceps-to-hamstring strength imbalance.
⸻
Common Injury Mechanisms
Typical mechanisms include:
Sprinting from starting blocks, clearing a hurdle, forceful jumping or take-off, sudden acceleration, rapid deceleration, and water-skiing falls.
⸻
Water-Skiing Injury
A classic water-skiing mechanism occurs when the hips are suddenly flexed while the knees remain extended, sometimes producing substantial proximal hamstring injury.
⸻
Associated Conditions
Hamstring injuries may coexist with other musculoskeletal problems, including lumbar strain and groin strain.
⸻
Diagnosis
⸻
History
The usual presentation is sudden posterior thigh pain during running, jumping, or another explosive activity.
⸻
Sudden Onset
Most patients describe an abrupt onset of pain and tenderness.
A smaller proportion may develop symptoms more gradually.
⸻
Pop
More severe injuries may be accompanied by a sudden pop or tearing sensation, followed by immediate weakness or inability to continue activity.
⸻
Signs and Symptoms
Common symptoms include:
Posterior thigh pain, tenderness, weakness, swelling, bruising, and difficulty walking or running.
Pain is generally aggravated by stretching the hamstrings or activating them against resistance.
⸻
Physical Examination
⸻
Gait
Patients may demonstrate a stiff-legged gait because they attempt to avoid simultaneous hip flexion and knee extension, which places the hamstrings on stretch.
⸻
Inspection
The posterior thigh should be examined for:
Swelling, bruising, ecchymosis, hematoma, contour abnormality, or a palpable defect.
Marked bruising may indicate a more substantial tear.
⸻
Palpation
The entire hamstring muscle-tendon complex should be palpated from the ischial tuberosity to the distal insertions.
The location of maximal tenderness helps identify the injured structure.
⸻
Resisted Knee Flexion
Pain or weakness with resisted knee flexion supports the diagnosis of hamstring injury.
⸻
Resisted Hip Extension
Pain with resisted hip extension may also occur, especially with proximal injury.
⸻
Stretch Testing
Passive hip flexion combined with knee extension stretches the hamstrings and may reproduce symptoms.
⸻
Pathological Findings
The injury spectrum ranges from microscopic muscle-fiber disruption to a partial or complete tear of the biceps femoris, semitendinosus, semimembranosus, or associated tendons.
⸻
Imaging
Imaging is not routinely required when the history and examination clearly indicate an uncomplicated muscle strain.
⸻
Plain Radiographs
Radiographs should be obtained when fracture or avulsion is suspected.
⸻
Pelvic Radiographs
In adolescents, pelvic radiographs may demonstrate an ischial tuberosity avulsion fracture.
⸻
Knee Radiographs
If symptoms are concentrated near the distal biceps femoris insertion, knee radiographs may demonstrate an associated fibular head avulsion fracture.
⸻
Femoral Radiographs
Plain films of the femur may be helpful when a fracture is suspected after significant trauma.
⸻
MRI
MRI can define the location, extent, and severity of muscle or tendon injury.
It is particularly useful when a complete tendon avulsion, substantial tear, or alternative diagnosis is suspected.
⸻
Stress Fracture
MRI can also differentiate a hamstring strain from an occult stress fracture.
⸻
Bone Scintigraphy
Bone scintigraphy can help distinguish stress fracture from soft-tissue injury, although MRI is generally preferred when available.
⸻
Differential Diagnosis
Important differential diagnoses include:
Acute fracture, stress fracture, muscle contusion, proximal hamstring tendon avulsion, ischial apophyseal avulsion, and other posterior thigh muscle injuries.
⸻
Referred Pain
In more chronic or atypical presentations, referred symptoms from the lumbar spine or hip should also be considered.
⸻
Treatment
⸻
General Principles
Most musculotendinous hamstring strains are treated nonoperatively.
Treatment progresses through phases according to pain, strength, flexibility, and functional recovery rather than following a rigid timeline.
⸻
Acute Phase
During approximately the first week, treatment focuses on controlling pain and swelling.
⸻
Initial Measures
Relative rest, ice, compression, and elevation may be used during the early symptomatic period.
Gentle pain-free motion should begin as tolerated.
⸻
Subacute Phase
As acute inflammation and pain improve, progressive rehabilitation begins.
⸻
Concentric Strengthening
Concentric strengthening can be introduced gradually, together with low-impact cross-training.
Exercises should remain below the threshold that produces significant pain.
⸻
Remodeling Phase
During subsequent weeks, rehabilitation emphasizes restoration of muscle length, strength, and neuromuscular control.
⸻
Stretching
More progressive hamstring stretching can be introduced once acute pain has settled.
⸻
Eccentric Strengthening
Eccentric strengthening is a central component of rehabilitation because the hamstrings must tolerate high eccentric loads during running.
⸻
Agility and Trunk Stabilization
Progressive agility drills and core or trunk stabilization exercises are useful for restoring dynamic lower-extremity control.
⸻
Functional Phase
Running and sport-specific training can resume gradually when the patient is pain free and has recovered adequate strength and motion.
⸻
Return to Sport
Return should be based on functional criteria rather than time alone.
The patient should demonstrate full or near-full range of motion, minimal or no tenderness, symmetric strength, and the ability to sprint and perform sport-specific tasks without pain.
⸻
Competitive Phase
Once full activity resumes, continued strengthening, flexibility training, and neuromuscular conditioning are important to reduce recurrence.
⸻
Activity
Initial rest should be followed by a gradual progression of activity according to symptoms and functional recovery.
Premature return to sprinting increases the risk of reinjury.
⸻
Physical Therapy
Physical therapy is useful for restoring motion, strength, flexibility, and sport-specific function.
⸻
Ice Massage
Ice massage may be used for short-term symptomatic relief during the early phase.
⸻
Therapeutic Modalities
Modalities such as ultrasound have historically been used, although rehabilitation should focus primarily on progressive exercise and functional restoration.
⸻
Aquatic Exercise
Water-based exercise may permit range-of-motion and conditioning work while reducing loading on the injured muscle.
⸻
Exercise Progression
Once soreness has improved, active range of motion can progress to resisted knee flexion, hip-extension exercises, eccentric loading, running drills, and sport-specific movements.
⸻
Medication
⸻
NSAIDs
NSAIDs such as ibuprofen or naproxen may provide short-term relief of pain and swelling.
They have not been shown to accelerate muscle healing and should be used primarily for symptomatic control.
⸻
Acetaminophen
Acetaminophen may be used as an alternative analgesic.
⸻
Biologic Treatments
Platelet-rich plasma and other biologic therapies have been investigated for hamstring injuries.
Evidence supporting routine use remains limited, and these treatments should not replace structured rehabilitation.
⸻
Surgery
Surgery is generally not indicated for uncomplicated musculotendinous junction strains.
⸻
Ischial Tuberosity Avulsion Fracture
Adolescent avulsion fractures require assessment of displacement and functional impairment.
⸻
Displacement
Historically, displacement greater than approximately 2 cm has been considered a possible indication for operative fixation, particularly in active patients.
Significantly displaced fractures have a greater risk of painful nonunion and persistent functional limitation.
⸻
Tendon Avulsion
Complete proximal hamstring tendon avulsions, particularly those involving multiple tendons with substantial retraction, may be considered for surgical repair.
Treatment depends on age, activity level, chronicity, degree of retraction, and functional deficit.
⸻
Referral
Evidence of complete tendon rupture, proximal tendon avulsion, substantial weakness, or a significantly displaced ischial avulsion fracture should prompt referral to an orthopaedic sports-medicine specialist.
⸻
Follow-Up
⸻
Prognosis
Most hamstring strains heal successfully with appropriate rehabilitation.
Recovery time depends on injury severity, location, previous injury, and functional demands.
⸻
Mild Strains
Mild strains may improve within several days to approximately 1 week.
⸻
Moderate Strains
Moderate injuries may require approximately 1–3 weeks or longer, depending on the size and location of the tear.
⸻
Severe Injuries
Severe injuries, tendon avulsions, or displaced ischial tuberosity avulsion fractures may require many weeks to several months before full return to high-level sport.
⸻
Complications
⸻
Recurrent Strain
Previous hamstring injury significantly increases the risk of another strain.
Recurrence is especially common when flexibility, eccentric strength, and sprinting capacity have not been fully restored.
⸻
Chronic Weakness
A significant untreated tendon injury may lead to persistent weakness, reduced endurance, and difficulty with high-speed activity.
⸻
Scar Formation
Healing may produce scar tissue that alters normal muscle-tendon mechanics and contributes to recurrent symptoms.
⸻
Symptomatic Nonunion
Substantially displaced ischial tuberosity avulsion fractures may fail to unite and produce chronic pain, weakness, or sitting discomfort.
⸻
Patient Monitoring
Patients should be followed according to symptom severity and athletic demands.
Monitoring should include pain, tenderness, range of motion, hamstring strength, gait, flexibility, running tolerance, and ability to perform sport-specific movements.
A long-term program of eccentric strengthening, flexibility work, trunk stabilization, and graded athletic conditioning should be continued after return to sport to reduce the risk of recurrence.
- Published on
Orthopaedic Surgery - Hammer Toes
Basics
A hammer toe is a lesser-toe deformity characterized primarily by flexion at the proximal interphalangeal (PIP) joint.
The distal interphalangeal (DIP) joint is usually extended, while the metatarsophalangeal (MTP) joint may remain neutral or become mildly extended.
The deformity may be flexible or rigid.
Epidemiology
Hammer toes are common and may be present in up to approximately 20% of patients presenting with foot disorders.
They occur more frequently in females than males.
Prevention
Because constrictive footwear is a major contributing factor, prevention focuses on wearing shoes with a wide, deep toe box that allows adequate room for the lesser toes.
Shoes that compress the forefoot or force the toes into a flexed position should be avoided.
Etiology
The most common cause is poorly fitting footwear, particularly shoes with a narrow or shallow toe box.
Other associated causes include:
Neuromuscular disease, diabetes mellitus, inflammatory arthropathy, and previous compartment syndrome.
Pathophysiology
Hammer toe develops from an imbalance between the intrinsic and extrinsic muscles and tendons controlling the lesser toes.
Abnormal forces progressively alter PIP and MTP alignment.
Initially, the deformity may remain flexible, but chronic imbalance can lead to capsular contracture and a fixed rigid deformity.
Associated Conditions
Hammer toes frequently coexist with other forefoot abnormalities.
Hallux Valgus
A bunion or hallux valgus deformity may crowd the lesser toes and contribute to development or progression of hammer toe.
MTP Hyperextension
When substantial MTP dorsiflexion accompanies the deformity, the clinical pattern may overlap with a claw toe.
Diagnosis
Diagnosis is primarily clinical.
The examination should define the location of deformity, degree of flexibility, associated MTP instability, and the source of pain.
Signs and Symptoms
Dorsal PIP Prominence
A prominent PIP joint is usually visible over the dorsum of the affected toe.
This prominence may rub against footwear.
Erythema
Repeated shoe pressure may produce localized redness over the prominent joint.
Callus Formation
A painful dorsal callus or corn may develop because of chronic pressure between the PIP prominence and the shoe.
History
Patients commonly report pain over the dorsal PIP prominence, particularly when wearing closed shoes.
Symptoms often improve with wider footwear or removal of the shoe.
Metatarsalgia
Some patients also develop pain beneath the metatarsal heads because altered toe mechanics transfer pressure to the plantar forefoot.
Physical Examination
Flexibility
The examiner should determine whether the deformity is flexible or rigid.
A flexible hammer toe can be passively corrected toward normal alignment, whereas a rigid deformity cannot.
MTP Joint
The MTP joint should be examined for dorsal subluxation, instability, or fixed hyperextension.
MTP instability may influence both treatment and prognosis.
Hallux Valgus
The foot should be inspected for an associated bunion deformity because hallux valgus can worsen crowding of the lesser toes.
Skin
The dorsal PIP joint and plantar forefoot should be examined for calluses, corns, ulceration, erythema, and pressure-related skin breakdown.
This is particularly important in patients with diabetes or neuropathy.
Imaging
Plain radiographs may confirm the PIP flexion deformity and demonstrate associated abnormalities such as MTP subluxation, hallux valgus, or degenerative change.
Weight-bearing views are generally most useful when overall forefoot alignment is being assessed.
Differential Diagnosis
Claw Toe
A claw toe usually demonstrates MTP hyperextension with flexion of both the PIP and DIP joints.
The MTP abnormality is typically more pronounced than in an isolated hammer toe.
Mallet Toe
A mallet toe consists primarily of flexion at the DIP joint.
The PIP joint is usually relatively neutral.
Treatment
General Principles
Treatment is directed toward symptoms rather than appearance alone.
Initial management is usually nonoperative and aims to reduce pressure on the prominent toe, accommodate the deformity, and improve comfort.
Footwear Modification
Shoes with a wide and high toe box should be used to minimize pressure over the dorsal PIP joint.
Avoidance of tight or pointed shoes is an important part of treatment.
Flexible Hammer Toe
A flexible deformity may improve symptomatically with a Budin splint or similar toe-straightening device.
The splint helps hold the toe in a more extended position and decreases dorsal pressure.
Rigid Hammer Toe
When the deformity is rigid, correction with a splint is less effective.
Treatment focuses on reducing local pressure.
Padding
Doughnut-shaped pads, silicone gel sleeves, and other protective devices may decrease friction and pressure over the dorsal prominence.
Geriatric Considerations
Hammer toes are particularly common in older women.
Many elderly patients also have medical conditions that increase operative risk or impair wound healing.
Diabetes and Vascular Disease
In patients with diabetes mellitus, peripheral neuropathy, or peripheral vascular disease, nonoperative treatment should be maximized whenever possible.
Skin integrity must be monitored closely because pressure points can progress to ulceration.
Surgery
Surgery is considered when persistent pain, shoe intolerance, ulceration, or progressive deformity continues despite appropriate nonoperative treatment.
The procedure depends largely on whether the toe remains flexible or has become rigid.
Flexible Hammer Toe Surgery
A flexor-to-extensor tendon transfer may be used for selected flexible deformities.
The procedure redirects flexor force to help extend the PIP joint and rebalance the toe.
Rigid Hammer Toe Surgery
Rigid deformities usually require a bony procedure.
Resection Arthroplasty
One of the most commonly performed operations is resection arthroplasty of the distal portion of the proximal phalanx.
The toe may then be temporarily stabilized with a pin while the soft tissues heal in corrected alignment.
Intramedullary Implants
Intramedullary fixation devices have increasingly been used as alternatives to external pins.
Potential advantages include avoidance of an exposed pin and improved patient convenience, although implant-related complications can still occur.
PIP Arthrodesis
Fusion of the PIP joint is another common option for painful rigid hammer toe.
It can be used both for primary correction and for revision of recurrent deformity.
Referral
Patients whose symptoms persist despite shoe modification, padding, or splinting may benefit from surgical consultation.
Diabetes
Patients with diabetes, neuropathy, or threatened skin breakdown should be assessed early because progressive pressure may lead to neuropathic ulceration or infection.
Prognosis
Hammer toe deformities commonly progress gradually over time.
Flexible deformities may become rigid as soft tissues contract.
Pain, callus formation, and difficulty wearing shoes may increase as the deformity worsens.
Complications
Potential postoperative complications include:
Stiffness, wound infection, persistent pain, incomplete correction, implant irritation, and recurrence of deformity.
Patient Monitoring
Follow-up should assess pain, shoe tolerance, skin condition, callus formation, flexibility of the toe, MTP stability, and progression of deformity.
Patients with diabetes or neuropathy require particularly careful surveillance for pressure-related skin breakdown and ulceration.
- Published on
Orthopaedic Surgery - Growth-Plate Injury
Basics
A growth-plate injury involves the physis, the cartilaginous region responsible for longitudinal growth of a child’s bone.
Not every physeal injury produces a growth abnormality. Most heal without long-term consequences, but injuries that significantly crush, displace, or destroy part of the growth plate may result in growth arrest, angular deformity, or limb-length discrepancy.
Common Sites
Physeal fractures occur most frequently in the long bones of growing children.
The growth plates most commonly injured include the:
Distal radius, distal tibia, phalanges, and proximal humerus.
Sites at Greatest Risk of Growth Disturbance
Although some physes are injured more frequently, the distal femoral and distal tibial physes are particularly important because injuries in these locations have a relatively high risk of subsequent growth disturbance.
Synonyms
Growth-plate injuries are also called physeal injuries or physeal fractures.
The term Salter-Harris fracture refers to the widely used classification system for traumatic injuries involving the physis.
Epidemiology
Physeal injuries account for approximately 15–30% of pediatric fractures.
They can occur throughout childhood but are particularly common during periods of rapid growth.
Age
Peak incidence generally occurs around 11–12 years in girls and 12–14 years in boys, corresponding approximately to the adolescent growth spurt.
Sex
Boys are affected more frequently overall, with some series reporting approximately twice as many injuries in boys as in girls.
Remaining Growth
Younger children have more growth remaining and therefore have a greater amount of potential deformity if a physeal arrest develops.
Conversely, a similar growth arrest occurring near skeletal maturity may have relatively little effect on final limb length or alignment.
Risk Factors
Adolescent boys are at increased risk because of their higher frequency of traumatic injuries during periods when the growth plate remains open.
Prevention of Sequelae
Early recognition of physeal damage may allow intervention before severe deformity develops.
Physeal Bar
A physeal bar is a bridge of bone that forms across part of an injured growth plate and can tether further growth.
If the bar is relatively small and the child has substantial growth remaining, surgical excision may allow more symmetric growth to resume.
Historically, bar resection has been considered when less than approximately 50% of the physis is involved, although candidacy also depends on bar location and remaining growth.
Other Corrective Options
When growth arrest has already produced substantial deformity, treatment may include:
Physeal bar resection, contralateral epiphysiodesis, ipsilateral hemiepiphysiodesis, corrective osteotomy, or limb-lengthening procedures.
Contralateral Epiphysiodesis
When a predictable limb-length discrepancy is expected, growth of the opposite limb may be intentionally slowed or stopped to improve final symmetry.
Etiology
Trauma is the most common cause of growth-plate injury.
Other processes may also damage the physis.
Nontraumatic Causes
Potential causes include:
Infection, tumor, medications or hormonal exposure, and severe thermal injury from excessive heat or cold.
Classification
The Salter-Harris classification is the standard system used to describe traumatic physeal fractures.
It is based on the relationship of the fracture line to the physis, metaphysis, and epiphysis.
Salter-Harris Type I
The fracture passes entirely through the physis, separating the epiphysis from the metaphysis without extending into either adjacent bone.
Because the germinal portion of the growth plate may remain intact, the prognosis is usually good after appropriate reduction.
Salter-Harris Type II
Type II is the most common physeal fracture pattern.
The fracture passes through the physis and then exits through the metaphysis, leaving a metaphyseal fragment attached to the epiphysis.
Salter-Harris Type III
The fracture passes from the physis through the epiphysis and into the joint surface.
Because it is intra-articular and crosses the growth plate, accurate reduction is important to restore both joint congruity and physeal alignment.
Salter-Harris Type IV
The fracture extends through the metaphysis, physis, and epiphysis, crossing the entire growth plate and entering the joint.
This pattern carries an increased risk of growth arrest and post-traumatic joint incongruity if reduction is inadequate.
Salter-Harris Type V
Type V represents a compression or crush injury of the physis.
It may be difficult to recognize on initial radiographs and is associated with a relatively high risk of premature growth arrest.
Rang Type VI
A so-called Type VI or Rang VI injury involves damage to the peripheral perichondral ring.
It is not part of the original Salter-Harris classification but may produce asymmetric growth and angular deformity.
Risk by Classification
In general, the risk of growth disturbance increases with increasing complexity of physeal injury.
Types III, IV, and V are particularly concerning because they either cross the articular surface, disrupt the germinal layer more extensively, or crush the physis.
Associated Injuries
Physeal trauma may occur with other injuries, including:
Ligament injury, neurovascular injury, and additional chest, abdominal, or head trauma in high-energy mechanisms.
Diagnosis
Accurate diagnosis requires knowledge of the normal appearance and timing of secondary ossification centers and physeal closure at each skeletal location.
A fracture may be difficult to identify if much of the epiphysis remains cartilaginous.
Signs and Symptoms
The most common findings are pain, swelling, and tenderness over the involved growth plate.
Visible deformity may be present if the fracture is displaced.
Lower-Extremity Injuries
Children with a lower-extremity physeal fracture may be unable or unwilling to bear weight.
Upper-Extremity Injuries
Upper-extremity fractures commonly produce pain, swelling, and reduced active range of motion.
Crepitus
Crepitus may occasionally be present but should not be deliberately elicited because repeated manipulation can worsen pain or displacement.
Physical Examination
The entire injured limb should be examined carefully.
Skin
The examiner should look for open wounds, abrasions, bruising, swelling, and skin compromise.
Any wound near a fracture should raise concern for an open injury.
Neurovascular Status
Distal pulses, capillary refill, sensation, and motor function should be documented before and after splinting or reduction.
Pathological Findings
The physis is organized into several histologic zones:
Resting zone, proliferative zone, hypertrophic zone, zone of provisional calcification, and adjacent metaphysis.
Site of Fracture Propagation
Many physeal fractures propagate through the relatively weak hypertrophic and provisional calcification regions.
Permanent Physeal Injury
Permanent growth disturbance may occur when the injury destroys growth-plate cells, causes marked displacement or malalignment of the physis, or produces a bony bridge across the plate.
Infection can similarly damage the growth plate and result in arrest.
Imaging
Plain Radiographs
Initial imaging should include AP and lateral radiographs of the involved region.
An oblique view may be useful when the fracture pattern remains unclear.
Comparison Views
Comparison with the opposite side may occasionally help in very young children, although this is not routinely required.
CT
CT is useful for complex fractures, particularly those with intra-articular extension, when precise definition of the fracture geometry is required for treatment planning.
It is especially valuable for Salter-Harris III and IV injuries around complex joints.
MRI
MRI is the most sensitive modality for evaluating established physeal damage, occult physeal injury, and physeal bars.
It clearly demonstrates cartilage and can distinguish the growth plate from surrounding bone.
Acute MRI Findings
Possible findings include:
Physeal widening, increased fluid-sensitive signal within the injured physis, and adjacent bone marrow edema.
Physeal Bar Mapping
MRI can define the size, position, and percentage of physeal involvement by a bony bridge.
Three-dimensional or semiautomated mapping may assist prognosis and surgical planning.
Ultrasound
Ultrasound can be useful in infants and very young children because substantial portions of the epiphysis remain cartilaginous and may not be visible on conventional radiographs.
Differential Diagnosis
In acute trauma, the primary concern is identifying whether the injury truly involves the physis.
In chronic cases, other causes of growth-plate damage must be considered.
Infection
Physeal or metaphyseal infection may be insidious and can produce growth disturbance long after the initial illness.
Other Causes
Tumor, metabolic disease, previous surgery, radiation, thermal injury, and prior trauma may also cause physeal arrest.
Treatment
Initial Measures
Immediate management includes immobilization, elevation, ice when appropriate, pain control, and assessment of neurovascular status.
Nondisplaced Fractures
Nondisplaced physeal fractures should be immobilized promptly in an appropriate splint.
Displaced Fractures
Displaced injuries generally require reduction under suitable analgesia or anesthesia.
Options may include procedural sedation, regional or hematoma block in appropriate fractures, or general anesthesia.
After reduction, the limb is splinted and repeat imaging is obtained to confirm alignment.
Early Follow-Up
Patients with physeal fractures should usually be reviewed within approximately 3–5 days, particularly when substantial swelling is present.
Splint to Cast Conversion
A splint is often used initially because it accommodates swelling.
After edema has decreased, commonly after approximately 1–2 weeks, a circumferential cast may be applied if continued immobilization is required.
Weight Bearing
Lower-extremity physeal fractures are often treated with restricted or non-weight bearing until adequate stability and healing are demonstrated.
Upper-extremity injuries are generally protected with a sling or other supportive device.
Duration of Immobilization
Many uncomplicated physeal fractures heal relatively quickly because of the vascularity and remodeling potential of children.
Immobilization frequently lasts approximately 3–4 weeks, although duration varies substantially by age, fracture location, stability, and treatment method.
Medication
Analgesia should be provided according to pain severity.
Persistent or escalating pain should prompt reassessment for complications such as compartment syndrome rather than simply increasing medication.
Surgery
Goal of Reduction
Restoring appropriate alignment is one of the most important methods of reducing the risk of later deformity.
For intra-articular physeal injuries, restoration of the joint surface is also essential.
Repeated Reduction Attempts
Repeated forceful reduction attempts should be avoided because additional manipulation may further injure the growth plate.
Delayed Reduction
Forceful closed reduction performed more than approximately 5–7 days after injury is generally avoided in many physeal fractures because healing has already begun and manipulation may damage the physis.
Management should instead be individualized according to deformity, fracture type, and remaining growth.
Open Reduction
Salter-Harris III and IV fractures may require open reduction when acceptable anatomic alignment cannot be achieved by closed techniques.
Internal Fixation
Fractures that remain unstable after reduction may require percutaneous pinning, screws, or other internal fixation.
Crossing the Physis
When fixation must cross an open physis, smooth pins placed as centrally and perpendicularly as practical are generally preferred because they minimize physeal injury.
Eccentric or threaded implants crossing the physis may increase the risk of growth disturbance.
Open Fractures
Open physeal fractures require urgent antibiotics, tetanus assessment, surgical irrigation and debridement, stabilization, and orthopaedic management.
Follow-Up
Prognosis
Most growth-plate fractures heal without major difficulty.
The likelihood of growth disturbance depends on fracture type, anatomic location, degree of displacement, quality of reduction, patient age, and extent of physeal injury.
Effect of Salter-Harris Type
Higher-grade Salter-Harris injuries generally have a greater risk of subsequent growth abnormality.
Effect of Skeletal Maturity
The closer the patient is to skeletal maturity, the less remaining growth exists and therefore the smaller the potential effect of a growth arrest on final limb length.
High-Risk Anatomic Sites
The distal femoral and distal tibial physes have relatively high rates of growth disturbance and warrant particularly careful follow-up.
Lower-Risk Sites
The distal radius and proximal humerus often tolerate physeal injury better because of their substantial remodeling potential and the pattern of growth at those sites, although growth arrest can still occur.
Complications
Growth Arrest
A portion or all of the physis may stop growing prematurely.
Complete arrest can produce limb shortening, whereas partial arrest may create progressive angular deformity.
Growth Disturbance
Asymmetric growth across an injured physis may result in varus, valgus, flexion, extension, or rotational deformity, depending on the location of the arrest.
Limb-Length Discrepancy
Loss of growth from a major physis may produce clinically significant shortening of the affected limb.
Malunion
A fracture that heals in poor alignment may produce deformity even without a true growth arrest.
Growth Acceleration
Children younger than approximately 10 years may occasionally demonstrate temporary overgrowth after fracture because of increased local blood flow and stimulation of growth.
The resulting length increase is usually modest, often approximately 5–10 mm.
Patient Monitoring
Children at increased risk of growth disturbance require prolonged surveillance.
This includes Salter-Harris III–V fractures and all significant distal femoral or distal tibial physeal injuries.
Duration
Follow-up should generally continue for at least 6–12 months, and longer when substantial growth remains or there is concern for partial arrest.
Clinical Assessment
The physician should compare limb lengths, angular alignment, gait, and joint motion.
Radiographic Assessment
Follow-up radiographs should assess whether the growth plate remains open and symmetric.
A growth-arrest line, sometimes called a Harris line, may form after the injury.
If subsequent growth is normal, this line should progressively move away from the physis in a parallel and symmetric fashion.
Failure of the line to migrate normally, or asymmetric tethering toward one side of the physis, may suggest developing growth arrest.
- Published on
Orthopaedic Surgery - Growing Pains
⸻
Basics
Growing pains are a common, benign, noninflammatory pain syndrome of childhood characterized by recurrent episodes of lower-extremity discomfort without objective musculoskeletal abnormalities.
Despite the name, the condition has not been shown to result directly from periods of rapid skeletal growth.
⸻
Typical Pattern
The pain usually occurs after active days and is most prominent during the late afternoon, evening, or nighttime.
Children may occasionally awaken from sleep because of the discomfort.
⸻
Resolution of Episodes
Each episode resolves completely.
The child is generally normal and pain free between episodes.
⸻
Location
Symptoms occur predominantly in the lower extremities and may involve one or both legs.
Pain is usually vague rather than sharply localized.
⸻
Frequency
Episodes occur unpredictably.
Pain-free intervals may last days, weeks, or even months.
Some severely affected children may experience symptoms almost daily.
⸻
Physical Findings
Growing pains produce no persistent objective abnormalities.
There should be no focal tenderness, swelling, joint restriction, weakness, or limp.
⸻
Synonyms
Other terms include benign nocturnal limb pains of childhood, leg aches, and night pains.
⸻
Epidemiology
Growing pains are very common.
Approximately 15–36% of children are reported to experience symptoms consistent with this syndrome at some point.
⸻
Age
The condition most commonly affects children between approximately 4 and 14 years of age.
⸻
Sex
Girls may be affected slightly more often than boys.
⸻
Risk Factors
⸻
High Activity Level
Symptoms are frequently reported in otherwise healthy, highly active children.
Episodes may be more noticeable after days involving substantial running, jumping, or sports participation.
⸻
Family History
A positive family history is common.
A parent or sibling has been reported to have experienced similar childhood pains in nearly 70% of cases in some series.
⸻
Etiology
The precise mechanism remains uncertain.
The disorder has been proposed to represent a form of relative musculoskeletal overuse or stress-related pain in otherwise normal children.
⸻
Possible Contributing Factors
Proposed contributors include increased physical activity, relatively reduced bone strength, altered pain perception, and a lower pain threshold.
None of these explanations completely accounts for the syndrome.
⸻
Diagnosis
Growing pains are a clinical diagnosis of exclusion.
The history and examination must be typical, and findings suggesting infection, inflammatory disease, malignancy, neurologic disease, or structural orthopaedic pathology should be absent.
⸻
Signs and Symptoms
⸻
Relationship to Activity
Pain frequently occurs after periods of increased activity.
Symptoms most often develop in the evening or at night.
⸻
Nocturnal Pain
Children may awaken because of discomfort, although they should return to normal function afterward.
Persistent morning pain is not typical.
⸻
Duration
Individual attacks may last from several minutes to several hours.
⸻
Laterality
Pain is commonly bilateral, although episodes may occasionally affect only one leg at a particular time.
⸻
Character
The pain is generally diffuse, vague, and poorly localized, often involving the calves, thighs, shins, or region behind the knees.
⸻
Severity
Pain intensity varies considerably.
Some children describe only mild aching, whereas others experience episodes severe enough to cry or awaken from sleep.
⸻
Episodic Course
A characteristic feature is the presence of completely pain-free intervals.
This episodic pattern helps distinguish growing pains from many inflammatory, infectious, neoplastic, or structural disorders.
⸻
Physical Examination
A careful examination is essential because growing pains should not produce abnormal findings.
⸻
Observation of Gait
The child should be observed walking naturally, preferably before becoming aware that gait is being assessed.
There should be no limp, stiffness, guarding, or reluctance to bear weight.
⸻
Palpation
The lower extremities should be palpated systematically.
Growing pains should not produce focal bony, muscular, or joint-line tenderness.
⸻
Range of Motion
Range of motion of the hips, knees, and ankles should be full and symmetric.
⸻
Hip Examination
Particular attention should be given to the hips because hip disease may initially present as vague thigh or knee pain.
Gentle internal and external rotation of the hip, sometimes called the roll test or log-roll test, should not produce guarding or restriction.
⸻
General Findings
There should be no swelling, erythema, warmth, muscle wasting, weakness, neurologic deficit, or systemic illness.
Any such finding should prompt investigation for another diagnosis.
⸻
Laboratory Tests
Routine laboratory testing is not necessary when the history and physical examination are entirely typical.
⸻
Atypical Presentation
If the history is unusual or concerning, investigations may include a complete blood count and inflammatory markers such as ESR and/or C-reactive protein.
Further testing should be directed toward the suspected alternative diagnosis.
⸻
Imaging
Routine imaging is unnecessary for classic growing pains.
⸻
Plain Radiographs
Radiographs may be obtained when pain is persistently localized, unilateral, associated with trauma, or accompanied by an abnormal examination.
⸻
Advanced Imaging
Bone scintigraphy or other advanced imaging may occasionally help localize an occult source of pain when the clinical picture is atypical.
MRI is often preferred when an occult infection, stress injury, tumor, or inflammatory condition is suspected.
⸻
Differential Diagnosis
Because growing pains are a diagnosis of exclusion, important alternative causes of childhood limb pain include:
Legg-Calvé-Perthes disease, chronic or subacute osteomyelitis, leukemia, sickle cell disease, juvenile idiopathic arthritis, Lyme disease, Osgood-Schlatter disease in older children, restless legs syndrome, and muscle cramps.
⸻
Other Concerning Diagnoses
Depending on the clinical setting, stress fracture, bone tumor, inflammatory arthropathy, infection, trauma, neurologic disease, and referred hip pain should also be considered.
⸻
Red Flags
Findings that are inconsistent with typical growing pains include persistent unilateral pain, focal tenderness, swelling, warmth, morning stiffness, joint restriction, limp, weakness, fever, weight loss, fatigue, night sweats, or progressively worsening symptoms.
These findings require further evaluation.
⸻
Treatment
⸻
Reassurance
Once the diagnosis is reasonably established, the most important treatment is reassurance of the child and family.
The condition is benign and does not damage bones, joints, or muscles.
⸻
Stretching
A regular stretching program may decrease the frequency of symptoms.
Useful stretches target the hamstrings, quadriceps, and calf muscles, particularly before bedtime.
⸻
Home Program
The stretching program can usually be performed with parental supervision and does not require formal physical therapy.
⸻
Activity Modification
Most children can remain active.
If symptoms become frequent or severe, temporary reduction of particularly strenuous activities may help bring discomfort into a tolerable range.
⸻
Orthoses
In selected children with substantial foot pronation or other biomechanical abnormalities, shoe inserts or orthotic devices may be considered.
However, orthoses are not routinely required for children with otherwise typical growing pains.
⸻
Physical Therapy
Formal physical therapy is generally unnecessary.
It may be helpful when flexibility is poor, symptoms persist despite a home stretching program, or another biomechanical problem is present.
⸻
Medication
Simple analgesics may be used occasionally for troublesome episodes.
Examples include acetaminophen or NSAIDs when appropriate.
Continuous routine medication is usually unnecessary.
⸻
Follow-Up
Children with a completely typical presentation generally require only limited follow-up.
Repeated visits may sometimes be useful when the diagnosis remains uncertain or when the evolving pattern of symptoms needs to be observed.
⸻
Prognosis
The prognosis is excellent.
Growing pains almost always resolve spontaneously as the child matures, without permanent musculoskeletal consequences.
⸻
Patient Monitoring
Parents should monitor the character, frequency, location, and timing of pain.
A simple symptom diary may be useful when episodes are frequent.
The stretching program can be continued, and activity may be adjusted according to symptom severity.
Reevaluation is appropriate if the pattern changes or if the child develops persistent focal pain, swelling, limp, fever, morning symptoms, weakness, or other objective abnormalities.
